{"gene":"HMGA1","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":2001,"finding":"HMGA1 proteins bind preferentially to the narrow minor groove of AT-rich DNA sequences via conserved peptide motifs called 'AT hooks', and can also interact with various protein transcription factors both in vitro and in vivo, forming stereospecific multiprotein complexes ('enhanceosomes') on gene promoter/enhancer regions. The proteins have little secondary structure in solution but assume distinct conformations when bound to DNA or other proteins.","method":"In vitro DNA binding assays, protein-protein interaction studies, structural analysis","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Strong — foundational mechanistic biochemical characterization replicated across multiple labs over many years; AT-hook DNA binding and conformational changes upon substrate binding established by multiple orthogonal methods","pmids":["11406267"],"is_preprint":false},{"year":1993,"finding":"The human HMG-I(Y) gene produces HMG-I and HMG-Y isoform proteins via alternative splicing of precursor mRNAs, with each of the three different DNA-binding AT-hook domains encoded by sequences on separate exons. Gene transcription is inducible in human lymphoid cells by phorbol esters and calcium ionophores.","method":"Gene cloning, sequencing, RT-PCR, chromosomal localization, induction experiments","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct molecular cloning and sequencing establishing gene structure; alternative splicing mechanism confirmed by exon-intron arrangement; inducible expression demonstrated experimentally","pmids":["8414980"],"is_preprint":false},{"year":2001,"finding":"HMGA1(Y) protein directly binds to AT-rich sequences in the 5' regulatory region of the human insulin receptor (INSR) gene, and is required for proper transcription of the INSR gene. Antisense HMGA1(Y) specifically inhibits insulin receptor promoter function and insulin receptor protein expression.","method":"Chromatographic purification, EMSA, immunoblot, CAT reporter gene assay, hormone binding studies with antisense RNA cells","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct biochemical purification combined with functional reporter assay and antisense knockdown showing loss of promoter activity and receptor expression; multiple orthogonal methods in single study","pmids":["11156965"],"is_preprint":false},{"year":2001,"finding":"HMGA1b protein overexpression deregulates the cell cycle (cells enter S-phase earlier, G2-M transition delayed) and induces apoptosis through caspase-3 activation in normal rat thyroid cells. The third AT-hook domain and acetylation site K60 are required for induction of apoptosis.","method":"Overexpression in PC Cl 3 cells, cell cycle analysis, apoptosis assays, caspase-3 activity measurement, site-directed mutagenesis of AT-hook domain and K60 acetylation site","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis identifying specific functional domains (AT-hook 3 and K60), combined with cell cycle and apoptosis readouts; multiple orthogonal methods in single study","pmids":["11389094"],"is_preprint":false},{"year":1995,"finding":"HMG-I(Y) proteins are in vivo substrates for cell cycle-regulated Cdc2 kinase, which phosphorylates the DNA-binding domain(s), decreasing their substrate binding affinity. This reversible phosphorylation during the cell cycle regulates HMGA1 biological function.","method":"In vivo and in vitro kinase assays, DNA binding assays","journal":"Progress in cell cycle research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase assays establishing Cdc2 phosphorylation of HMGA1 DNA-binding domain with functional consequence on binding affinity; single review but describing prior experimental work","pmids":["9552376"],"is_preprint":false},{"year":2002,"finding":"HMGA1 protein synthesis is required for thyroid cell transformation by Kirsten murine sarcoma virus. Blockage of HMGA1 via antisense construct prevents the malignant phenotype (anchorage-independent growth, tumor formation) and correlates with absence of AP-1 transcriptional activity induction.","method":"Antisense HMGA1 cDNA transfection, soft agar colony formation assay, tumor formation in athymic mice, AP-1 reporter assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined cellular and molecular phenotype readouts (no transformation, no AP-1 activity); in vitro and in vivo confirmation","pmids":["12082527"],"is_preprint":false},{"year":2003,"finding":"HMGA1 proteins directly control GATA-1 transcription, negatively regulating it. Loss of HMGA1 in embryonic stem cells causes overexpression of GATA-1, resulting in altered hematopoietic differentiation (reduced monocyte/macrophage population, increased megakaryocyte precursors, increased erythropoiesis). Re-expression of HMGA1 in null ES cells restores wild-type phenotype.","method":"Hmga1-null ES cell differentiation assays, gene expression analysis, re-expression rescue experiment","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout and rescue experiments establishing HMGA1 as direct transcriptional regulator of GATA-1 with defined hematopoietic differentiation phenotype; multiple lineage readouts","pmids":["12824305"],"is_preprint":false},{"year":2006,"finding":"HMGA1 directly regulates cardiomyocytic cell growth; haploinsufficiency of Hmga1 in mice causes cardiac hypertrophy. HMGA1 loss also leads to increased RAG1/2 endonuclease expression, abnormal IgH rearrangements, B cell expansion, and hematologic malignancies (B cell lymphoma and myeloid leukemia).","method":"Hmga1 heterozygous and homozygous knockout mice, cardiac phenotyping, hematologic analysis, gene expression studies","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo genetic loss-of-function with defined molecular and cellular phenotypes; heterozygous and homozygous mice analyzed","pmids":["16510570"],"is_preprint":false},{"year":2007,"finding":"HMGA1 physically binds the small pocket domain of retinoblastoma protein (RB) and competes with HDAC1 for RB binding. HMGA1 overexpression abolishes RB-mediated repression of E2F-activated transcription from the cyclin E promoter and abrogates RB-mediated G0 arrest under serum starvation.","method":"Co-immunoprecipitation, reporter gene assay (cyclin E promoter), serum starvation G0 arrest assay, overexpression in T98G cells","journal":"Cancer science","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal protein interaction data combined with functional promoter reporter and cell cycle arrest assay; direct competition with HDAC1 for RB pocket domain established","pmids":["17877762"],"is_preprint":false},{"year":2008,"finding":"HMGA1 protein is a novel target of the ATM kinase. An SQ motif on HMGA1 is effectively phosphorylated by ATM in vitro and in vivo. HMGA1 colocalizes with activated ATM (ATM S1981p) and HMGA1 ectopic expression decreases cell survival following ionizing radiation.","method":"In vitro and in vivo kinase assays, confocal microscopy colocalization, clonogenic survival assay after ionizing radiation","journal":"European journal of cancer","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro kinase assay identifying SQ phosphorylation site, confirmed in vivo, plus colocalization and functional consequence (reduced survival after IR); multiple orthogonal methods","pmids":["18783938"],"is_preprint":false},{"year":2009,"finding":"HMGA1 physically interacts with retinoblastoma protein (RB), C/EBPbeta, and HDAC1. The HMGA1/RB interaction is required for adipocyte differentiation: HMGA1 displaces HDAC1 from the RB-E2F1 complex, enabling CDC25A and CDC6 promoter activation. RB, C/EBPbeta, and HMGA1 cooperate to regulate Id1 and leptin gene transcription. Hmga1-/- ES cells fail to undergo adipocyte differentiation.","method":"Co-immunoprecipitation, reporter gene assays (leptin, Id1, CDC25A, CDC6 promoters), Hmga1-/- ES cell differentiation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct protein-protein interaction via Co-IP, multiple promoter reporter assays, genetic knockout phenotype, and displacement of HDAC1 from RB-E2F1 complex established; mechanistic detail confirmed by multiple approaches","pmids":["19633359"],"is_preprint":false},{"year":2009,"finding":"HMGA1 reversibly migrates from nuclei to mitochondria during late S/G2 phases of the cell cycle in normal cells, where it binds mitochondrial DNA (mtDNA). In cancer cells, this controlled shuttling is lost and HMGA1 is found in mitochondria throughout the cell cycle. Elevated HMGA1 levels inversely correlate with mtDNA levels and mitochondrial mass, increase reactive oxygen species (ROS), and decrease efficiency of oxidatively damaged mtDNA repair.","method":"Inducible transgenic HMGA1 expression system in MCF-7 cells, mitochondrial fractionation, mtDNA quantification, ROS measurement, mtDNA repair assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — controlled inducible expression system with turn-ON/turn-OFF experiments, subcellular fractionation, multiple functional readouts (mtDNA levels, mass, ROS, repair efficiency); robust mechanistic study","pmids":["19687300"],"is_preprint":false},{"year":2010,"finding":"HMGA1 is a positive regulator of IGF-IR gene transcription. HMGA1 binds directly to the IGF-IR promoter (ChIP assay) and associates with p53 and Sp1. HMGA1 antagonizes p53 inhibitory activity while enhancing Sp1 stimulatory activity on the igf-ir promoter. Silencing HMGA1 decreases IGF-IR expression; forced HMGA1 overexpression increases it.","method":"ChIP assay, promoter activity assays, Co-immunoprecipitation (association with p53 and Sp1), siRNA knockdown and overexpression","journal":"European journal of cancer","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct ChIP establishing promoter binding, protein-protein interaction via Co-IP, loss- and gain-of-function with functional readouts; multiple orthogonal methods","pmids":["20335021"],"is_preprint":false},{"year":2010,"finding":"7SK small nuclear RNA directly interacts with HMGA1, specifically through the loop 2 (7SK L2) region binding to the first AT-hook motif of HMGA1, competing with DNA binding to the same domain. This interaction regulates over 1500 HMGA1 target genes and affects HMGA1-dependent cell differentiation and proliferation.","method":"RNA-protein interaction assays, transcriptome-wide profiling, 7SK substructure inhibition experiments","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct RNA-protein interaction assay identifying specific 7SK loop 2 binding to AT-hook 1 of HMGA1, with competition against DNA binding and genome-wide transcriptional consequences demonstrated","pmids":["21087998"],"is_preprint":false},{"year":2011,"finding":"HMGA1 and P-TEFb cooperate in transcriptional activation of select target genes. 7SK RNA complexes containing simultaneously HMGA1 and P-TEFb were identified. 7SK RNA establishes gene-dependent plasticity between HMGA1 chromatin remodeling/transcription initiation and P-TEFb transcription elongation.","method":"Transcriptome profiling, dominant-negative Cdk9 inhibition, RNA immunoprecipitation of 7SK complexes containing both HMGA1 and P-TEFb","journal":"RNA biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-IP detecting ternary complexes, transcriptome profiling of gene co-regulation; single lab but multiple approaches","pmids":["21957495"],"is_preprint":false},{"year":2011,"finding":"HMGA1a can cross-link different DNA molecules simultaneously through a novel DNA cross-linking domain identified by point mutagenesis. Overexpression of HMGA1a-eGFP causes chromatin aggregation. Electron microscopy showed HMGA1 creates DNA loops and supercoils in linearized DNA.","method":"dSTORM super-resolution microscopy, DNA cross-linking assay, point mutagenesis, electron microscopy","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — novel in vitro cross-linking assay with mutagenesis identifying cross-linking domain, confirmed by super-resolution microscopy and electron microscopy; multiple orthogonal structural/biochemical methods","pmids":["21596776"],"is_preprint":false},{"year":2012,"finding":"HMGA1 binds directly to the COX-2 promoter at an AT-rich region in vivo in pancreatic cancer cell lines (ChIP assay) and induces COX-2 expression. Knockdown of HMGA1 represses COX-2. HMGA1 cooperates with activated K-RAS to induce migration, invasion, and anchorage-independent growth.","method":"ChIP assay (in vivo promoter binding), siRNA knockdown, overexpression, migration/invasion assays, xenograft tumor formation","journal":"Pancreatology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct in vivo promoter occupancy by ChIP, loss-of-function phenotype, in vivo xenograft confirmation; multiple orthogonal methods","pmids":["22898640"],"is_preprint":false},{"year":2013,"finding":"HMGA1 specifically binds to the HIV-1 TAR element, with the binding interface overlapping the Tat binding site. HMGA1 and Tat compete for TAR binding. 7SK RNA competes with TAR for HMGA1. HMGA1 negatively influences expression from HIV-1 promoter in a TAR-dependent manner in the presence and absence of Tat.","method":"RNA binding assays, competition experiments, HIV-1 promoter reporter assays, HMGA1 knockdown","journal":"RNA biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct RNA binding assay and competition with Tat established, reporter assays confirm TAR-dependent transcriptional regulation; single lab","pmids":["23392246"],"is_preprint":false},{"year":2014,"finding":"HMGA1 recruits the inactive 7SK/P-TEFb snRNP to cellular gene promoters and the HIV-1 promoter. CTIP2 represses P-TEFb activity in a complex containing 7SK RNA and HEXIM1. HMGA1 knockdown causes loss of CTIP2/7SK/P-TEFb snRNP recruitment to these promoters as shown by ChIP.","method":"Chromatin immunoprecipitation (ChIP), siRNA double knockdown, luciferase reporter assay","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating HMGA1-dependent promoter recruitment of inactive P-TEFb complex, combined with double-knockdown epistasis; direct mechanism for P-TEFb recruitment established","pmids":["24623795"],"is_preprint":false},{"year":2015,"finding":"HMGA1 proteins are able to increase the expression of spindle assembly checkpoint (SAC) genes Ttk, Mad2l1, Bub1, and Bub1b by binding to their promoter regions. HMGA1 depletion causes SAC gene downregulation and mitotic defects including unaligned chromosomes in metaphase, reduced prometaphase time, delayed anaphase, and cytokinesis failure.","method":"ChIP assay (promoter binding), siRNA knockdown, live-cell microscopy, gene expression analysis","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct ChIP showing HMGA1 promoter occupancy at SAC genes, live-cell microscopy revealing specific mitotic defects upon depletion; multiple genes and orthogonal methods","pmids":["26009897"],"is_preprint":false},{"year":2016,"finding":"miR-296-5p is repressed in a DNA methylation-dependent manner in glioblastoma stem cells. HMGA1 functions as a downstream effector of miR-296-5p and regulates Sox2 expression by modifying chromatin architecture at the Sox2 promoter, thereby regulating glioblastoma stem cell self-renewal.","method":"miR-296-5p overexpression/inhibition, HMGA1 knockdown, chromatin architecture assay at Sox2 promoter, glioma xenograft model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — HMGA1 shown to modulate Sox2 promoter chromatin architecture and act as downstream effector; functional xenograft validation; single lab","pmids":["26898758"],"is_preprint":false},{"year":2016,"finding":"miR-26 silences HMGA1 (and MALT1), thereby dampening NF-κB signaling and TNF-α-induced IL-6 transcription. Knocking down both HMGA1 and MALT1 by RNAi produces NF-κB gene silencing similar to miR-26 overexpression.","method":"Transcriptome-wide miR-26 manipulation, RNAi knockdown of HMGA1 and MALT1, NF-κB reporter assay, IL-6 expression analysis","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi epistasis experiment placing HMGA1 in NF-κB signaling downstream of miR-26; transcriptome-wide approach with functional validation; single lab","pmids":["27025651"],"is_preprint":false},{"year":2017,"finding":"Hmga1 amplifies Wnt/β-catenin signaling to enhance intestinal stem cell self-renewal by upregulating genes encoding Wnt agonist receptors and downstream Wnt effectors. Hmga1 also directly induces Sox9, which is required for Paneth cell differentiation, thereby 'building' an intestinal stem cell niche.","method":"Hmga1 transgenic mouse model, gene expression analysis (RNA-seq), ChIP, intestinal organoid assays, in vivo tumor/crypt analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic model combined with ChIP, RNA-seq, and organoid functional assays; multiple orthogonal approaches confirming Wnt amplification and Sox9 induction mechanisms","pmids":["28452345"],"is_preprint":false},{"year":2017,"finding":"HMGA1 is a novel transcriptional regulator of the FoxO1 gene. HMGA1 binds directly to the FoxO1 gene promoter (ChIP) and activates FoxO1 gene transcription, increasing FoxO1 mRNA and protein levels in hepatocytes. Forced HMGA1 expression in Hmga1-/- primary hepatocytes rescues FoxO1 expression.","method":"Reporter gene assays, ChIP, qRT-PCR, Western blot, primary hepatocyte culture from Hmga1-/- mice, siRNA knockdown","journal":"Endocrine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct ChIP establishing promoter occupancy, reporter assay, and rescue in knockout hepatocytes; multiple orthogonal methods in single study","pmids":["29052178"],"is_preprint":false},{"year":2017,"finding":"G9a/EHMT2 histone methyltransferase modulates hepatic insulin signaling through regulation of HMGA1 expression. G9a knockdown reduces HMGA1 levels and impairs insulin receptor/AKT signaling; overexpression of HMGA1 normalizes impaired insulin signaling in G9a knockdown cells. In db/db mice, restoring G9a upregulates HMGA1 and improves hepatic insulin signaling.","method":"G9a siRNA knockdown, HMGA1 overexpression rescue, insulin signaling assays (p-AKT, insulin receptor), in vivo db/db mouse model","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis placing G9a upstream of HMGA1 in insulin signaling; rescue experiment; confirmed in vivo; single lab","pmids":["29101051"],"is_preprint":false},{"year":2017,"finding":"HMGA1 directly regulates the transcription of PLAU (urokinase) and SERPINE1 (PAI-1), key components of the Plasminogen activation system. HMGA1 silencing alters the breast cancer cell secretome, reducing pro-migratory and pro-invasive secreted factors.","method":"Inducible HMGA1 silencing, iTRAQ LC-MS/MS secretome profiling, promoter binding assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteome-scale secretome profiling combined with direct promoter regulation assays for PLAU and SERPINE1; single lab","pmids":["28924209"],"is_preprint":false},{"year":2018,"finding":"Extracellular HMGA1 (eHMGA1) becomes a ligand for the receptor RAGE (Advanced glycosylation end product-specific receptor), inducing pERK signaling and increasing migration and invasion of triple-negative breast cancer cells. Antibodies blocking HMGA1 in the extracellular space impair migration and invasion.","method":"HMGA1-blocking antibodies, RAGE receptor binding assays, pERK signaling assay, migration/invasion assays, xenograft models, fluorescence microscopy","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct ligand-receptor interaction established with functional signaling readout (pERK); blocking antibody experiments confirm extracellular function; in vivo xenograft validation","pmids":["30135148"],"is_preprint":false},{"year":2019,"finding":"PD-L1 directly interacts with HMGA1 in colorectal cancer cells, and HMGA1 upregulation by PD-L1 activates PI3K/Akt and MEK/ERK pathways to promote cancer stem cell expansion and self-renewal. HMGA1 downregulation rescues PD-L1-induced cancer stem cell phenotypes.","method":"Co-immunoprecipitation (PD-L1-HMGA1 interaction), Western blot (pathway analysis), tumorsphere assays, HMGA1 knockdown rescue experiments, xenograft mouse model","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single Co-IP establishing interaction, functional rescue experiment and in vivo confirmation; multiple readouts but interaction characterized by single method","pmids":["30776481"],"is_preprint":false},{"year":2019,"finding":"HMGA1 negatively regulates NUMB expression at both transcriptional and post-transcriptional levels in glioblastoma stem cells. At the transcriptional level, HMGA1 binds the NUMB promoter and counteracts C/EBP-β. At the post-transcriptional level, HMGA1 regulates MSI1 and miR-146a expression. HMGA1 knockdown-induced NUMB upregulation leads to downregulation of the NOTCH1 pathway.","method":"ChIP (HMGA1 binding to NUMB promoter), C/EBP-β competition assay, miR-146a/MSI1 expression analysis, shRNA knockdown, NOTCH1 pathway analysis","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP establishing direct promoter binding and C/EBP-β competition; multiple levels of regulation shown; single lab","pmids":["31116627"],"is_preprint":false},{"year":2020,"finding":"HMGA1 overexpression in cardiomyocytes aggravates LPS-induced inflammation and apoptosis by upregulating cyclooxygenase-2 (COX-2). COX-2 inhibitor alleviates this aggravation. HMGA1 knockdown attenuates inflammation but aggravates apoptosis via downregulation of STAT3; STAT3 agonist reverses the anti-inflammatory effect of HMGA1 knockdown but ameliorates LPS-induced apoptosis.","method":"Adeno-associated virus-mediated HMGA1 overexpression in mouse heart, siRNA knockdown in H9c2 cells, COX-2 inhibitor treatment, STAT3 agonist treatment, LPS stimulation, cardiac function assay","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro gain/loss-of-function experiments with pharmacological rescue (COX-2 inhibitor, STAT3 agonist); dual pathway mechanism dissected; single lab","pmids":["32398950"],"is_preprint":false},{"year":2021,"finding":"HMGA1 transcriptionally activates RAD51 by binding directly to its promoter through two HMGA1 response elements. HMGA1 overexpression promotes radioresistance in cholangiocarcinoma, while HMGA1 knockdown causes radiosensitivity. Inhibition of RAD51 reverses the effect of HMGA1 on radioresistance.","method":"ChIP assay (HMGA1 binding to RAD51 promoter through response elements), RAD51 inhibition rescue experiments, clonogenic survival assay after X-ray irradiation, overexpression/knockdown experiments","journal":"Cell death discovery","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct ChIP establishing binding to specific RAD51 promoter response elements, rescue experiment with RAD51 inhibitor, functional radioresistance assay; multiple orthogonal methods","pmids":["34716319"],"is_preprint":false},{"year":2022,"finding":"HMGA1 chromatin regulators transactivate GATA2 through sequences near the developmental +9.5 enhancer, increasing chromatin accessibility and recruiting active histone marks (H3K4me3, H3K27Ac). Silencing GATA2 recapitulates most phenotypes of HMGA1 depletion in MPN, and GATA2 re-expression partially rescues leukemogenesis. HMGA1 depletion prevents MPN progression to myelofibrosis in JAK2V617F mice.","method":"CRISPR/Cas9, shRNA, and genetic deletion; RNA-sequencing; ChIP-sequencing (HMGA1 occupancy and histone marks); JAK2V617F mouse model; GATA2 rescue experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-seq defining HMGA1 occupancy and active histone marks at GATA2 enhancer; multiple genetic approaches (CRISPR, shRNA, knockout); in vivo mouse model; epistasis via GATA2 rescue; highly rigorous study","pmids":["35286385"],"is_preprint":false},{"year":2023,"finding":"HMGA1 directly induces FGF19 expression by recruiting active histone marks (H3K4me3, H3K27Ac) to the FGF19 gene, increasing FGF19 secretion. Disrupting FGF19 (by gene silencing or FGFR4 inhibitor BLU9931) recapitulates HMGA1 deficiency phenotypes: decreased tumor growth and reduced desmoplastic stroma formation in pancreatic cancer models.","method":"RNA-sequencing, ChIP (HMGA1 binding and histone marks at FGF19), siRNA gene silencing, FGFR4 inhibitor treatment, KPC mouse model, orthotopic/subcutaneous xenograft models","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP showing HMGA1 recruitment of active histone marks at FGF19 locus; multiple in vivo mouse models; pharmacological and genetic epistasis; rigorous multi-method study","pmids":["36919699"],"is_preprint":false},{"year":2024,"finding":"HMGA1 acts as a chromatin remodeling factor that promotes binding of activating transcription factor 4 (ATF4) to the SLC7A11 promoter, enhancing SLC7A11 transcription and maintaining intracellular glutathione homeostasis, thereby suppressing ferroptosis and conferring cisplatin resistance in esophageal squamous cell carcinoma.","method":"Transcriptome analysis, ChIP assay (HMGA1 and ATF4 at SLC7A11 promoter), ferroptosis assays (MDA measurement, glutathione levels), HMGA1 knockout in syngeneic allograft and genetically engineered mouse models","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP establishing HMGA1-facilitated ATF4 binding at SLC7A11 promoter, mechanistic ferroptosis assays, in vivo mouse model validation; multiple orthogonal methods","pmids":["38383528"],"is_preprint":false},{"year":2024,"finding":"HMGA1 increases transcriptional activity of SREBP1 on the FASN promoter, leading to increased lipid accumulation and fatty acid synthesis. Conditional knockout of Hmga1 in intestinal epithelium reduces FASN expression and tumor development in a CRC mouse model, while pharmacological FASN inhibition by orlistat reduces tumor growth in HMGA1-overexpressing mice.","method":"Conditional knockout (Hmga1△IEC) and knock-in (Hmga1IEC-OE/+) mouse models, AOM/DSS-induced CRC model, dual-luciferase reporter assay (FASN promoter), Western blot, orlistat treatment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional genetic mouse models (KO and KI) combined with promoter reporter assay; pharmacological rescue with FASN inhibitor; in vivo validation; rigorous multi-method approach","pmids":["39548107"],"is_preprint":false},{"year":2024,"finding":"NAT10 enhances HMGA1 mRNA stability by catalyzing N4-acetylcytidine (ac4C) modification of HMGA1 mRNA, thereby promoting cell cycle progression and prostate cancer cell proliferation.","method":"ac4C acetylation assays, mRNA stability assays, NAT10 knockdown/overexpression, prostate cancer cell proliferation assays","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA modification identified with NAT10 as writer enzyme; mRNA stability consequence established; single lab","pmids":["38922788"],"is_preprint":false},{"year":2024,"finding":"HMGA1 drives a specific 3D chromatin organization: HMGA1-dense loci form highly interactive networks, sequestering genes into 3D networks. HMGA1 heterogeneous linear distribution controls high-order chromatin compartmentalization. In the absence of HMGA1, this 3D organization is largely reversed and inflammatory senescence-associated secretory phenotype (SASP) signaling is amplified.","method":"Functional genomics (ChIP-seq, Hi-C/3D genome analysis), graph theory analysis, oncogene-induced senescence model, HMGA1 depletion","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — genome-wide ChIP-seq and 3D chromatin organization analysis (Hi-C) combined with functional senescence model and graph theory; mechanistic link between HMGA1 distribution and chromatin compartmentalization established","pmids":["39134516"],"is_preprint":false},{"year":2021,"finding":"GRP75 directly binds to HMGA1 protein and inhibits ubiquitination-mediated HMGA1 degradation, thereby stabilizing HMGA1 and causing its upregulation. The GRP75/HMGA1 axis activates JNK/c-JUN signaling in lung adenocarcinoma.","method":"Co-immunoprecipitation (GRP75-HMGA1 interaction), ubiquitination assay, GRP75/HMGA1 overexpression and knockdown, JNK/c-JUN pathway analysis, mRNA-sequencing","journal":"Thoracic cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct Co-IP and ubiquitination assay establishing GRP75 as a regulator of HMGA1 protein stability; downstream pathway confirmed; single lab","pmids":["33755320"],"is_preprint":false},{"year":2019,"finding":"HMGA1 promotes expression of miR-222, which in turn activates PI3K/Akt/MMP9 pathway in uveal melanoma. HMGA1 positively regulates both miR-222 and the PI3K/Akt/MMP9 pathway components in vitro and in vivo.","method":"Western blotting, RT-PCR, immunochemistry, xenograft mouse model, miR-222 mimic/inhibitor transfection","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — functional epistasis placing HMGA1 upstream of miR-222 and PI3K/Akt/MMP9, with in vivo confirmation; relationship between HMGA1 and miR-222 identified by bioinformatics and confirmed functionally; single lab","pmids":["31394192"],"is_preprint":false},{"year":2016,"finding":"HMGA1 is a polymorphic regulator of VEGFA expression. The HMGA1 rs139876191 variant adversely affects HMGA1 protein expression and function, leading to downregulation of VEGFA expression and protection against proliferative diabetic retinopathy.","method":"Case-control association study, HMGA1 variant functional analysis, VEGFA expression assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — functional variant study linking HMGA1 to VEGFA expression regulation; mechanistic link established through protein expression and function assays; single study","pmids":["27991577"],"is_preprint":false},{"year":2007,"finding":"HMGA1 is required for maximal activation of the CRYAB (alphaB-crystallin) promoter by the SWI/SNF chromatin remodeling complex BRG1. HMGA1 binds in vitro and in vivo to an AT-rich sequence within a 30 bp BRG1-response element located at the edge of a positioned nucleosome upstream of the transcription start site.","method":"ChIP (HMGA1 binding in vivo), in vitro DNA binding assays, HMGA1 knockdown, promoter mutational analysis, BRG1 overexpression","journal":"DNA and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo binding confirmed by ChIP; functional requirement for HMGA1 in BRG1-mediated activation established by knockdown and promoter mutation; single lab","pmids":["17723105"],"is_preprint":false},{"year":2022,"finding":"HMGA1 promotes macrophage recruitment in hepatocellular carcinoma by activating NF-κB signaling, which in turn drives CCL2 expression. Pharmacological or genetic inhibition of NF-κB blocks CCL2 upregulation in HMGA1-overexpressing HCC cells. Macrophage depletion with clodronate liposomes abrogates the tumor-promoting effects of HMGA1.","method":"NF-κB pharmacological/genetic inhibition, CCL2 quantification (ELISA, qRT-PCR, Western blot), clodronate liposome macrophage depletion, orthotopic HCC xenograft model","journal":"Journal of immunology research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic NF-κB inhibition epistasis; macrophage depletion confirms the pathway in vivo; CCL2 as mechanistic output; single lab","pmids":["35785026"],"is_preprint":false}],"current_model":"HMGA1 is a non-histone architectural chromatin protein that binds AT-rich DNA via three AT-hook motifs (competing with 7SK RNA for the same domain), bends and cross-links DNA, and functions as a dynamic scaffold for stereospecific enhanceosome assembly on gene promoters; it directly transactivates or represses diverse target genes (INSR, IGF-IR, FoxO1, COX-2, FGF19, GATA2, RAD51, Sox9, SLC7A11, FASN, and others) by recruiting co-activators (Sp1, C/EBPβ, ATF4, SREBP1) or displacing repressors (HDAC1 from RB-E2F1 complexes); its activity is regulated post-translationally by Cdc2-mediated phosphorylation of AT-hook domains (reducing DNA binding during mitosis), ATM-mediated phosphorylation at an SQ motif after DNA damage, ubiquitination (counteracted by GRP75), and ac4C acetylation of its mRNA by NAT10 (increasing stability); HMGA1 also shuttles to mitochondria during late S/G2 to bind mtDNA and regulate mtDNA repair and mitochondrial mass, and secreted extracellular HMGA1 acts as a RAGE ligand to activate pERK signaling and promote cancer cell invasion."},"narrative":{"mechanistic_narrative":"HMGA1 is a non-histone architectural chromatin protein that binds the narrow minor groove of AT-rich DNA through conserved AT-hook motifs, adopts defined conformations only upon substrate binding, and nucleates stereospecific multiprotein 'enhanceosome' complexes on gene regulatory regions [PMID:11406267, PMID:8414980]. Beyond simple recognition, it actively reshapes DNA and chromatin: a discrete cross-linking domain lets it bridge separate DNA molecules into loops and supercoils [PMID:21596776], and at genome scale it organizes high-order 3D chromatin compartments, sequestering HMGA1-dense loci into interactive networks whose loss reverses compartmentalization and amplifies senescence-associated inflammatory signaling [PMID:39134516]. Acting as a recruiting scaffold, HMGA1 directly occupies the promoters/enhancers of a broad target set and tunes their output by deploying co-activators or histone-mark machinery—activating IGF-IR via Sp1 while antagonizing p53 [PMID:20335021], inducing FoxO1 [PMID:29052178], RAD51 [PMID:34716319], GATA2 through active H3K4me3/H3K27Ac at the +9.5 enhancer [PMID:35286385], FGF19 [PMID:36919699], and facilitating ATF4 loading at SLC7A11 and SREBP1 activity at FASN [PMID:38383528, PMID:39548107]—and repressing targets such as GATA-1 and NUMB, the latter by counteracting C/EBPβ [PMID:12824305, PMID:31116627]. It also cooperates with the SWI/SNF remodeler BRG1 at positioned nucleosomes [PMID:17723105] and competes with HDAC1 for the RB pocket to relieve RB-mediated repression of E2F targets, driving cell-cycle entry and enabling adipocyte differentiation [PMID:17877762, PMID:19633359]. Through these activities HMGA1 governs cell-cycle progression and spindle-assembly-checkpoint gene expression [PMID:11389094, PMID:26009897], stem-cell self-renewal via Wnt/β-catenin amplification and Sox9 induction [PMID:28452345], and tumor-promoting programs spanning invasion, metabolism, and DNA-damage resistance. HMGA1 function is constrained by post-translational and RNA-based regulation: Cdc2 phosphorylates the AT-hooks to lower DNA-binding affinity during the cell cycle [PMID:9552376], ATM phosphorylates an SQ motif after DNA damage [PMID:18783938], GRP75 binding blocks ubiquitin-mediated degradation [PMID:33755320], NAT10-catalyzed ac4C modification stabilizes its mRNA [PMID:38922788], and 7SK snRNA loop 2 binds AT-hook 1 in direct competition with DNA to reroute thousands of target genes and to deliver the inactive 7SK/P-TEFb snRNP to promoters [PMID:21087998, PMID:24623795]. HMGA1 additionally shuttles to mitochondria in late S/G2 to bind mtDNA and modulate mtDNA repair, mitochondrial mass, and ROS [PMID:19687300], and when secreted acts extracellularly as a RAGE ligand activating pERK to promote cancer cell invasion [PMID:30135148].","teleology":[{"year":1993,"claim":"Establishing the gene architecture explained how a single locus generates the HMG-I/HMG-Y isoforms and that each AT-hook DNA-binding domain is encoded on a separate exon, framing HMGA1 as a modular, inducibly expressed DNA-binding protein.","evidence":"Molecular cloning, sequencing, RT-PCR, and induction experiments in human lymphoid cells","pmids":["8414980"],"confidence":"High","gaps":["Did not define the in vivo DNA targets of the isoforms","Functional differences between HMG-I and HMG-Y isoforms not resolved"]},{"year":1995,"claim":"Identifying Cdc2 phosphorylation of the DNA-binding domains showed that HMGA1 DNA-binding affinity is cell-cycle-regulated, providing the first post-translational control switch for its architectural activity.","evidence":"In vivo/in vitro kinase assays and DNA binding assays (review of experimental work)","pmids":["9552376"],"confidence":"Medium","gaps":["Specific phosphorylated residues and quantitative affinity change not detailed in this source","Functional consequence on specific target genes not tested"]},{"year":2001,"claim":"Biochemical and structural characterization established the core mechanism—AT-hook recognition of the AT-rich minor groove, disorder-to-order transition upon binding, and assembly of enhanceosomes—and linked it directly to transcription via the insulin receptor promoter and to cell-cycle/apoptosis control via defined domains.","evidence":"In vitro DNA binding and protein interaction studies; INSR promoter purification, EMSA, CAT reporter and antisense; overexpression with AT-hook 3 and K60 mutagenesis in rat thyroid cells","pmids":["11406267","11156965","11389094"],"confidence":"High","gaps":["High-resolution structure of HMGA1 on DNA not resolved","How enhanceosome co-factor selection is determined not defined"]},{"year":2002,"claim":"Loss-of-function showed HMGA1 is required for oncogenic transformation, establishing it as a functional driver rather than a passive chromatin component, with AP-1 transcriptional activity as a downstream readout.","evidence":"Antisense HMGA1 with soft-agar, athymic mouse tumor formation, and AP-1 reporter in Kirsten sarcoma virus-transformed thyroid cells","pmids":["12082527"],"confidence":"High","gaps":["Direct HMGA1 target genes mediating transformation not pinpointed","Mechanistic link to AP-1 not at the DNA-binding level"]},{"year":2003,"claim":"Knockout-and-rescue established HMGA1 as a direct negative transcriptional regulator of GATA-1 controlling hematopoietic lineage choice, demonstrating physiological developmental function.","evidence":"Hmga1-null ES cell differentiation, expression analysis, and re-expression rescue","pmids":["12824305"],"confidence":"High","gaps":["Direct promoter occupancy at GATA-1 not shown here","Co-factors mediating repression not identified"]},{"year":2006,"claim":"In vivo mouse genetics showed Hmga1 dosage controls cardiomyocyte growth and lymphoid genome integrity (RAG1/2, IgH rearrangement), expanding its role to tissue homeostasis and tumor suppression at reduced dosage.","evidence":"Hmga1 heterozygous/homozygous knockout mice with cardiac and hematologic phenotyping","pmids":["16510570"],"confidence":"High","gaps":["Direct transcriptional targets driving each phenotype not all defined","Mechanism of RAG1/2 derepression unresolved"]},{"year":2007,"claim":"Demonstrating HMGA1 binding to the RB pocket in competition with HDAC1, and cooperation with BRG1, established HMGA1 as a regulator of the RB-E2F axis and a partner of chromatin-remodeling machinery.","evidence":"Co-IP, cyclin E and CRYAB promoter reporters, G0 arrest assay, ChIP, and BRG1 overexpression","pmids":["17877762","17723105"],"confidence":"High","gaps":["Stoichiometry of RB/HDAC1/HMGA1 competition not quantified","Whether BRG1 cooperation generalizes beyond CRYAB not tested"]},{"year":2008,"claim":"Identifying ATM phosphorylation of an HMGA1 SQ motif placed HMGA1 within the DNA-damage response and tied its expression to radiation survival.","evidence":"In vitro/in vivo kinase assays, confocal colocalization with ATM S1981p, clonogenic survival after ionizing radiation","pmids":["18783938"],"confidence":"High","gaps":["Functional consequence of SQ phosphorylation on DNA binding or chromatin not defined","Downstream repair targets not connected here"]},{"year":2009,"claim":"Mechanistic dissection in adipogenesis showed HMGA1 displaces HDAC1 from RB-E2F1 to activate CDC25A/CDC6 and cooperates with RB and C/EBPβ on leptin/Id1, while a parallel study revealed cell-cycle-coupled mitochondrial shuttling and mtDNA regulation, broadening HMGA1 beyond nuclear chromatin.","evidence":"Co-IP, multiple promoter reporters, Hmga1-/- ES adipocyte differentiation; inducible MCF-7 system with mitochondrial fractionation, mtDNA/ROS/repair assays","pmids":["19633359","19687300"],"confidence":"High","gaps":["Mechanism targeting HMGA1 to mitochondria not defined","How loss of regulated shuttling in cancer is established not explained"]},{"year":2010,"claim":"ChIP and interaction studies established HMGA1 as a direct IGF-IR promoter activator that antagonizes p53 and enhances Sp1, and the discovery of 7SK snRNA binding AT-hook 1 revealed a competitive RNA switch governing thousands of target genes.","evidence":"ChIP, promoter assays, Co-IP with p53/Sp1; RNA-protein interaction mapping to 7SK loop 2 with transcriptome profiling","pmids":["20335021","21087998"],"confidence":"High","gaps":["Structural basis of 7SK loop 2/AT-hook 1 recognition not resolved","Genome-wide rules for DNA-versus-7SK occupancy not defined"]},{"year":2011,"claim":"Showing HMGA1 forms 7SK complexes with P-TEFb and possesses an intrinsic DNA cross-linking domain connected its transcriptional output to elongation control and revealed direct DNA-bridging/looping as a structural mechanism.","evidence":"RNA-IP of HMGA1/P-TEFb 7SK complexes, dominant-negative Cdk9, transcriptome profiling; cross-linking assay, point mutagenesis, dSTORM and electron microscopy","pmids":["21957495","21596776"],"confidence":"High","gaps":["How gene-by-gene plasticity between initiation and elongation is decided not defined","Physiological extent of DNA cross-linking in vivo not quantified"]},{"year":2013,"claim":"Demonstrating HMGA1 binding to HIV-1 TAR in competition with Tat, and 7SK competition with TAR, extended the competitive AT-hook/RNA model to viral transcriptional control.","evidence":"RNA binding and competition assays, HIV-1 promoter reporters, HMGA1 knockdown","pmids":["23392246"],"confidence":"Medium","gaps":["Single-lab finding awaiting independent confirmation","Physiological relevance during infection not established"]},{"year":2014,"claim":"ChIP and double-knockdown epistasis established that HMGA1 recruits the inactive CTIP2/7SK/HEXIM1/P-TEFb snRNP to cellular and HIV-1 promoters, defining a direct mechanism for delivering elongation machinery to chromatin.","evidence":"ChIP, siRNA double knockdown, luciferase reporter assays","pmids":["24623795"],"confidence":"High","gaps":["Trigger for converting recruited P-TEFb from inactive to active not defined","Generality across the genome not mapped"]},{"year":2015,"claim":"ChIP plus live-cell imaging showed HMGA1 directly activates spindle-assembly-checkpoint genes (Ttk, Mad2l1, Bub1, Bub1b), linking its transcriptional role to mitotic fidelity.","evidence":"ChIP, siRNA knockdown, live-cell microscopy, expression analysis","pmids":["26009897"],"confidence":"High","gaps":["Co-factors at SAC gene promoters not identified","Whether mitotic defects are direct or secondary not fully resolved"]},{"year":2017,"claim":"Multiple in vivo and metabolic studies positioned HMGA1 as a hub linking stem-cell niche formation, hepatic insulin signaling, and the secretome—amplifying Wnt and inducing Sox9, activating FoxO1, lying downstream of G9a, and directly driving PLAU/SERPINE1.","evidence":"Hmga1 transgenic mice, organoids, ChIP/RNA-seq; ChIP and rescue in Hmga1-/- hepatocytes; G9a knockdown rescue and db/db mice; secretome iTRAQ LC-MS/MS with promoter assays","pmids":["28452345","29052178","29101051","28924209"],"confidence":"High","gaps":["How a single chromatin factor selects such distinct programs in different tissues not defined","Some links (G9a, secretome) from single labs"]},{"year":2018,"claim":"Identifying secreted HMGA1 as a RAGE ligand activating pERK established an extracellular, receptor-mediated function distinct from its chromatin role.","evidence":"Blocking antibodies, RAGE binding and pERK assays, migration/invasion, xenografts, microscopy in triple-negative breast cancer","pmids":["30135148"],"confidence":"High","gaps":["Mechanism of HMGA1 secretion not defined","Structural basis of HMGA1-RAGE binding not resolved"]},{"year":2019,"claim":"A cluster of cancer studies wired HMGA1 into PD-L1, NUMB/NOTCH, and miR-222/PI3K-Akt-MMP9 circuits, showing both upstream regulation of HMGA1 and its function as a chromatin-level effector counteracting C/EBPβ at NUMB.","evidence":"Co-IP (PD-L1), tumorsphere and rescue assays; ChIP at NUMB with C/EBPβ competition and miR-146a/MSI1 analysis; miR-222 mimic/inhibitor with xenografts","pmids":["30776481","31116627","31394192"],"confidence":"Medium","gaps":["PD-L1-HMGA1 interaction rests on a single Co-IP without reciprocal validation","Directness of HMGA1 effects on miR-222 not established"]},{"year":2021,"claim":"ChIP-defined direct activation of RAD51 and identification of GRP75 as a stabilizer blocking HMGA1 ubiquitination connected HMGA1 to DNA-repair-mediated radioresistance and to control of its own protein turnover.","evidence":"ChIP at RAD51 response elements, RAD51-inhibitor rescue, clonogenic survival; Co-IP, ubiquitination assay, JNK/c-JUN pathway analysis","pmids":["34716319","33755320"],"confidence":"High","gaps":["E3 ligase targeting HMGA1 not identified","GRP75 axis from a single Medium-confidence study"]},{"year":2022,"claim":"ChIP-seq and genetic rescue established HMGA1 transactivation of GATA2 at the +9.5 enhancer with deposition of active histone marks as a driver of myeloproliferative neoplasm progression, and a parallel HCC study tied HMGA1 to NF-κB/CCL2-driven macrophage recruitment.","evidence":"CRISPR/shRNA/knockout, RNA-seq, ChIP-seq, JAK2V617F mice, GATA2 rescue; NF-κB inhibition, CCL2 quantification, clodronate macrophage depletion, orthotopic HCC model","pmids":["35286385","35785026"],"confidence":"High","gaps":["How HMGA1 directs histone-mark machinery to specific enhancers not defined","HCC NF-κB axis from a single Medium-confidence study"]},{"year":2023,"claim":"ChIP showed HMGA1 directly induces FGF19 by recruiting active histone marks, with FGF19/FGFR4 mediating tumor growth and desmoplastic stroma, reinforcing HMGA1 as an organizer of active chromatin states at growth-factor loci.","evidence":"RNA-seq, ChIP at FGF19, siRNA and FGFR4 inhibitor (BLU9931), KPC and xenograft pancreatic cancer models","pmids":["36919699"],"confidence":"High","gaps":["The writer machinery HMGA1 recruits for H3K4me3/H3K27Ac not identified","Whether FGF19 induction is fully cell-autonomous not resolved"]},{"year":2024,"claim":"A convergent set of studies defined HMGA1 as a chromatin-remodeling facilitator of metabolic and 3D-genome programs—loading ATF4 at SLC7A11 to suppress ferroptosis, boosting SREBP1 at FASN for lipogenesis, shaping high-order chromatin compartments, and being stabilized at the mRNA level by NAT10-mediated ac4C.","evidence":"ChIP and ferroptosis assays with KO mouse models (SLC7A11); conditional KO/KI mice and FASN reporter/orlistat (FASN); ChIP-seq/Hi-C senescence model; ac4C and mRNA stability assays with NAT10 manipulation","pmids":["38383528","39548107","39134516","38922788"],"confidence":"High","gaps":["How HMGA1 linear distribution is read into 3D compartmentalization mechanistically not defined","NAT10/ac4C regulation from a single Medium-confidence study"]},{"year":null,"claim":"A unifying mechanism for how a single AT-hook architectural protein selects its enormous, context-specific target repertoire—and how its phosphorylation, ubiquitination, ac4C, and 7SK-RNA inputs are integrated to switch between DNA bending, co-factor recruitment, and active-mark deposition—remains undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of HMGA1 engaging chromatin or co-factors","No predictive rule for tissue-specific target selection","Mechanism of mitochondrial import and secretion uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,2,12,15,16,19,23,30,31,40]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[13,14,17,18]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,6,12,23,30,31,32,33,34]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[26]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,2,11,31,36]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[15,36]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[11]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[26]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,12,18,23,31,32]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[15,31,32,36,40]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[3,4,8,10,19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[21,26,27,41]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,10,22]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[11,33,34]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[9,30]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,16,31,32]}],"complexes":["7SK/P-TEFb snRNP (HMGA1-recruited, with CTIP2/HEXIM1)","HMGA1-enhanceosome"],"partners":["RB1","HDAC1","CEBPB","SP1","TP53","ATF4","RAGE","GRP75"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P17096","full_name":"High mobility group protein HMG-I/HMG-Y","aliases":["High mobility group AT-hook protein 1","High mobility group protein A1","High mobility group protein R"],"length_aa":107,"mass_kda":11.7,"function":"HMG-I/Y bind preferentially to the minor groove of A+T rich regions in double-stranded DNA. It is suggested that these proteins could function in nucleosome phasing and in the 3'-end processing of mRNA transcripts. They are also involved in the transcription regulation of genes containing, or in close proximity to A+T-rich regions","subcellular_location":"Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/P17096/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/HMGA1","classification":"Common Essential","n_dependent_lines":1123,"n_total_lines":1208,"dependency_fraction":0.929635761589404},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000137309","cell_line_id":"CID001843","localizations":[{"compartment":"chromatin","grade":3},{"compartment":"nucleoplasm","grade":3},{"compartment":"nucleolus_gc","grade":1}],"interactors":[{"gene":"MTA2","stoichiometry":0.2},{"gene":"H2AFY","stoichiometry":0.2},{"gene":"BANF1","stoichiometry":0.2},{"gene":"PSIP1","stoichiometry":0.2},{"gene":"H1F0","stoichiometry":0.2},{"gene":"POLB","stoichiometry":0.2},{"gene":"WHSC1","stoichiometry":0.2},{"gene":"ACTL6A","stoichiometry":0.2},{"gene":"KPNA3","stoichiometry":0.2},{"gene":"SUPT5H","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001843","total_profiled":1310},"omim":[{"mim_id":"616456","title":"INO80 COMPLEX, SUBUNIT B; INO80B","url":"https://www.omim.org/entry/616456"},{"mim_id":"612893","title":"STATURE QUANTITATIVE TRAIT LOCUS 19; STQTL19","url":"https://www.omim.org/entry/612893"},{"mim_id":"611419","title":"SMALL INTEGRAL MEMBRANE PROTEIN 29; SMIM29","url":"https://www.omim.org/entry/611419"},{"mim_id":"609704","title":"MICRO RNA 16-1; MIR16-1","url":"https://www.omim.org/entry/609704"},{"mim_id":"604478","title":"CHROMOBOX 5; CBX5","url":"https://www.omim.org/entry/604478"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear membrane","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"esophagus","ntpm":268.3}],"url":"https://www.proteinatlas.org/search/HMGA1"},"hgnc":{"alias_symbol":[],"prev_symbol":["HMGIY"]},"alphafold":{"accession":"P17096","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P17096","model_url":"https://alphafold.ebi.ac.uk/files/AF-P17096-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P17096-F1-predicted_aligned_error_v6.png","plddt_mean":65.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HMGA1","jax_strain_url":"https://www.jax.org/strain/search?query=HMGA1"},"sequence":{"accession":"P17096","fasta_url":"https://rest.uniprot.org/uniprotkb/P17096.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P17096/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P17096"}},"corpus_meta":[{"pmid":"11406267","id":"PMC_11406267","title":"HMGI/Y proteins: flexible regulators of transcription and chromatin structure.","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11406267","citation_count":313,"is_preprint":false},{"pmid":"8414980","id":"PMC_8414980","title":"Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene.","date":"1993","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/8414980","citation_count":185,"is_preprint":false},{"pmid":"30776481","id":"PMC_30776481","title":"PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30776481","citation_count":166,"is_preprint":false},{"pmid":"26980699","id":"PMC_26980699","title":"The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.","date":"2016","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26980699","citation_count":102,"is_preprint":false},{"pmid":"11035986","id":"PMC_11035986","title":"Structure and function of the HMGI(Y) family of architectural transcription factors.","date":"2000","source":"Environmental health perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/11035986","citation_count":96,"is_preprint":false},{"pmid":"16510570","id":"PMC_16510570","title":"Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16510570","citation_count":93,"is_preprint":false},{"pmid":"30614613","id":"PMC_30614613","title":"HMGA1 in cancer: Cancer classification by location.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30614613","citation_count":89,"is_preprint":false},{"pmid":"27025651","id":"PMC_27025651","title":"MiR-26 down-regulates TNF-α/NF-κB signalling and IL-6 expression by silencing HMGA1 and MALT1.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27025651","citation_count":88,"is_preprint":false},{"pmid":"11156965","id":"PMC_11156965","title":"Transcriptional regulation of human insulin receptor gene by the high-mobility group protein HMGI(Y).","date":"2001","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/11156965","citation_count":84,"is_preprint":false},{"pmid":"12082527","id":"PMC_12082527","title":"Thyroid cell transformation requires the expression of the HMGA1 proteins.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12082527","citation_count":77,"is_preprint":false},{"pmid":"22053823","id":"PMC_22053823","title":"HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis.","date":"2011","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/22053823","citation_count":77,"is_preprint":false},{"pmid":"25268743","id":"PMC_25268743","title":"HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25268743","citation_count":74,"is_preprint":false},{"pmid":"21364139","id":"PMC_21364139","title":"Functional variants of the HMGA1 gene and type 2 diabetes mellitus.","date":"2011","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/21364139","citation_count":72,"is_preprint":false},{"pmid":"21138859","id":"PMC_21138859","title":"Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21138859","citation_count":72,"is_preprint":false},{"pmid":"19729480","id":"PMC_19729480","title":"HMGA1 is induced by Wnt/beta-catenin pathway and maintains cell proliferation in gastric cancer.","date":"2009","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19729480","citation_count":72,"is_preprint":false},{"pmid":"12807722","id":"PMC_12807722","title":"HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas.","date":"2003","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/12807722","citation_count":71,"is_preprint":false},{"pmid":"28452345","id":"PMC_28452345","title":"HMGA1 amplifies Wnt signalling and expands the intestinal stem cell compartment and Paneth cell niche.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28452345","citation_count":70,"is_preprint":false},{"pmid":"12824305","id":"PMC_12824305","title":"Loss of Hmga1 gene function affects embryonic stem cell lympho-hematopoietic differentiation.","date":"2003","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/12824305","citation_count":69,"is_preprint":false},{"pmid":"15569996","id":"PMC_15569996","title":"HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15569996","citation_count":66,"is_preprint":false},{"pmid":"9824199","id":"PMC_9824199","title":"HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors.","date":"1998","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9824199","citation_count":64,"is_preprint":false},{"pmid":"26898758","id":"PMC_26898758","title":"Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2 expression and glioblastoma stem cells.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26898758","citation_count":61,"is_preprint":false},{"pmid":"35864955","id":"PMC_35864955","title":"High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35864955","citation_count":57,"is_preprint":false},{"pmid":"30135148","id":"PMC_30135148","title":"Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30135148","citation_count":57,"is_preprint":false},{"pmid":"36978140","id":"PMC_36978140","title":"HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma.","date":"2023","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/36978140","citation_count":54,"is_preprint":false},{"pmid":"29618461","id":"PMC_29618461","title":"Lessons from the Crypt: HMGA1-Amping up Wnt for Stem Cells and Tumor Progression.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29618461","citation_count":52,"is_preprint":false},{"pmid":"30034366","id":"PMC_30034366","title":"Transcriptional Regulation of Glucose Metabolism: The Emerging Role of the HMGA1 Chromatin Factor.","date":"2018","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30034366","citation_count":48,"is_preprint":false},{"pmid":"21087998","id":"PMC_21087998","title":"7SK small nuclear RNA directly affects HMGA1 function in transcription regulation.","date":"2010","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/21087998","citation_count":48,"is_preprint":false},{"pmid":"32398950","id":"PMC_32398950","title":"The effect of HMGA1 in LPS-induced Myocardial Inflammation.","date":"2020","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32398950","citation_count":47,"is_preprint":false},{"pmid":"24623795","id":"PMC_24623795","title":"HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/24623795","citation_count":47,"is_preprint":false},{"pmid":"36919699","id":"PMC_36919699","title":"HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36919699","citation_count":43,"is_preprint":false},{"pmid":"38922788","id":"PMC_38922788","title":"NAT10 Promotes Prostate Cancer Growth and Metastasis by Acetylating mRNAs of HMGA1 and KRT8.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38922788","citation_count":40,"is_preprint":false},{"pmid":"26895108","id":"PMC_26895108","title":"HMGA1-pseudogenes and cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26895108","citation_count":38,"is_preprint":false},{"pmid":"25483074","id":"PMC_25483074","title":"HMGA1-pseudogene overexpression contributes to cancer progression.","date":"2014","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/25483074","citation_count":38,"is_preprint":false},{"pmid":"11389094","id":"PMC_11389094","title":"Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11389094","citation_count":38,"is_preprint":false},{"pmid":"29101051","id":"PMC_29101051","title":"Histone methyltransferase G9a modulates hepatic insulin signaling via regulating HMGA1.","date":"2017","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29101051","citation_count":38,"is_preprint":false},{"pmid":"11076660","id":"PMC_11076660","title":"Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status.","date":"2000","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11076660","citation_count":38,"is_preprint":false},{"pmid":"38383528","id":"PMC_38383528","title":"HMGA1 drives chemoresistance in esophageal squamous cell carcinoma by suppressing ferroptosis.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38383528","citation_count":37,"is_preprint":false},{"pmid":"28393241","id":"PMC_28393241","title":"TGF-β1 induces HMGA1 expression: The role of HMGA1 in thyroid cancer proliferation and invasion.","date":"2017","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28393241","citation_count":36,"is_preprint":false},{"pmid":"21984063","id":"PMC_21984063","title":"HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis.","date":"2011","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21984063","citation_count":35,"is_preprint":false},{"pmid":"27008379","id":"PMC_27008379","title":"The association between S100A13 and HMGA1 in the modulation of thyroid cancer proliferation and invasion.","date":"2016","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27008379","citation_count":35,"is_preprint":false},{"pmid":"26806308","id":"PMC_26806308","title":"miR-625 suppresses cell proliferation and migration by targeting HMGA1 in breast cancer.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26806308","citation_count":35,"is_preprint":false},{"pmid":"27486901","id":"PMC_27486901","title":"HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells.","date":"2016","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/27486901","citation_count":35,"is_preprint":false},{"pmid":"31394192","id":"PMC_31394192","title":"HMGA1 exacerbates tumor progression by activating miR-222 through PI3K/Akt/MMP-9 signaling pathway in uveal melanoma.","date":"2019","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/31394192","citation_count":34,"is_preprint":false},{"pmid":"35286385","id":"PMC_35286385","title":"HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/35286385","citation_count":33,"is_preprint":false},{"pmid":"22898640","id":"PMC_22898640","title":"The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma.","date":"2012","source":"Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/22898640","citation_count":33,"is_preprint":false},{"pmid":"20335021","id":"PMC_20335021","title":"HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene.","date":"2010","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/20335021","citation_count":32,"is_preprint":false},{"pmid":"26117853","id":"PMC_26117853","title":"RNA-Mediated Regulation of HMGA1 Function.","date":"2015","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/26117853","citation_count":31,"is_preprint":false},{"pmid":"22503056","id":"PMC_22503056","title":"Expression and role of HMGA1 in renal cell carcinoma.","date":"2012","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/22503056","citation_count":31,"is_preprint":false},{"pmid":"27991577","id":"PMC_27991577","title":"A polymorphism of HMGA1 protects against proliferative diabetic retinopathy by impairing HMGA1-induced VEGFA expression.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27991577","citation_count":31,"is_preprint":false},{"pmid":"28924209","id":"PMC_28924209","title":"HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28924209","citation_count":31,"is_preprint":false},{"pmid":"11410365","id":"PMC_11410365","title":"Sequence and analysis of the murine Hmgiy (Hmga1) gene locus.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11410365","citation_count":30,"is_preprint":false},{"pmid":"10526529","id":"PMC_10526529","title":"Expression of HMGIY in three uterine leiomyomata with complex rearrangements of chromosome 6.","date":"1999","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10526529","citation_count":30,"is_preprint":false},{"pmid":"10404089","id":"PMC_10404089","title":"Expression of the HMGI(Y) gene in human colorectal cancer.","date":"1999","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10404089","citation_count":30,"is_preprint":false},{"pmid":"26411793","id":"PMC_26411793","title":"HMGA1 overexpression in adipose tissue impairs adipogenesis and prevents diet-induced obesity and insulin resistance.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26411793","citation_count":30,"is_preprint":false},{"pmid":"32344629","id":"PMC_32344629","title":"HMGA1-Regulating microRNAs Let-7a and miR-26a are Downregulated in Human Seminomas.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32344629","citation_count":28,"is_preprint":false},{"pmid":"18783938","id":"PMC_18783938","title":"HMGA1 protein is a novel target of the ATM kinase.","date":"2008","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/18783938","citation_count":28,"is_preprint":false},{"pmid":"21957495","id":"PMC_21957495","title":"7SK snRNA-mediated, gene-specific cooperativity of HMGA1 and P-TEFb.","date":"2011","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/21957495","citation_count":28,"is_preprint":false},{"pmid":"31229266","id":"PMC_31229266","title":"HMGA1 promoting gastric cancer oncogenic and glycolytic phenotypes by regulating c-myc expression.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31229266","citation_count":27,"is_preprint":false},{"pmid":"19687300","id":"PMC_19687300","title":"HMGA1 levels influence mitochondrial function and mitochondrial DNA repair efficiency.","date":"2009","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19687300","citation_count":27,"is_preprint":false},{"pmid":"27839822","id":"PMC_27839822","title":"HMGA1 is a novel candidate gene for myocardial infarction susceptibility.","date":"2016","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/27839822","citation_count":27,"is_preprint":false},{"pmid":"29980789","id":"PMC_29980789","title":"HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29980789","citation_count":26,"is_preprint":false},{"pmid":"17877762","id":"PMC_17877762","title":"High mobility group protein HMGA1 inhibits retinoblastoma protein-mediated cellular G0 arrest.","date":"2007","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/17877762","citation_count":26,"is_preprint":false},{"pmid":"32477928","id":"PMC_32477928","title":"Downregulation of HMGA1 Mediates Autophagy and Inhibits Migration and Invasion in Bladder Cancer via miRNA-221/TP53INP1/p-ERK Axis.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32477928","citation_count":26,"is_preprint":false},{"pmid":"39548107","id":"PMC_39548107","title":"High mobility group A1 (HMGA1) promotes the tumorigenesis of colorectal cancer by increasing lipid synthesis.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39548107","citation_count":25,"is_preprint":false},{"pmid":"9552376","id":"PMC_9552376","title":"Cell cycle regulation and functions of HMG-I(Y).","date":"1995","source":"Progress in cell cycle research","url":"https://pubmed.ncbi.nlm.nih.gov/9552376","citation_count":25,"is_preprint":false},{"pmid":"31779212","id":"PMC_31779212","title":"Clinical Implications of Extracellular HMGA1 in Breast Cancer.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31779212","citation_count":24,"is_preprint":false},{"pmid":"31116627","id":"PMC_31116627","title":"HMGA1 negatively regulates NUMB expression at transcriptional and post transcriptional level in glioblastoma stem cells.","date":"2019","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/31116627","citation_count":24,"is_preprint":false},{"pmid":"21596776","id":"PMC_21596776","title":"Cross-linking of DNA through HMGA1 suggests a DNA scaffold.","date":"2011","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/21596776","citation_count":24,"is_preprint":false},{"pmid":"28255268","id":"PMC_28255268","title":"Regulatory Axis of miR-195/497 and HMGA1-Id3 Governs Muscle Cell Proliferation and Differentiation.","date":"2017","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28255268","citation_count":24,"is_preprint":false},{"pmid":"23392246","id":"PMC_23392246","title":"HMGA1 directly interacts with TAR to modulate basal and Tat-dependent HIV transcription.","date":"2013","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/23392246","citation_count":24,"is_preprint":false},{"pmid":"26009897","id":"PMC_26009897","title":"Deregulation of HMGA1 expression induces chromosome instability through regulation of spindle assembly checkpoint genes.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26009897","citation_count":23,"is_preprint":false},{"pmid":"26834854","id":"PMC_26834854","title":"Association of SIRT1 and HMGA1 expression in non-small cell lung cancer.","date":"2015","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26834854","citation_count":23,"is_preprint":false},{"pmid":"33169939","id":"PMC_33169939","title":"Circ_0067835 sponges miR-324-5p to induce HMGA1 expression in endometrial carcinoma cells.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33169939","citation_count":23,"is_preprint":false},{"pmid":"20459557","id":"PMC_20459557","title":"Increased expression of HMGA1 correlates with tumour invasiveness and proliferation in human pituitary adenomas.","date":"2010","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/20459557","citation_count":23,"is_preprint":false},{"pmid":"15923078","id":"PMC_15923078","title":"Molecular mechanism of HMGA1 deregulation in human neuroblastoma.","date":"2005","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15923078","citation_count":22,"is_preprint":false},{"pmid":"34167089","id":"PMC_34167089","title":"HMGA1 promotes gastric cancer growth and metastasis by transactivating SUZ12 and CCDC43 expression.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/34167089","citation_count":22,"is_preprint":false},{"pmid":"29052178","id":"PMC_29052178","title":"HMGA1 is a novel transcriptional regulator of the FoxO1 gene.","date":"2017","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/29052178","citation_count":22,"is_preprint":false},{"pmid":"39134516","id":"PMC_39134516","title":"HMGA1 orchestrates chromatin compartmentalization and sequesters genes into 3D networks coordinating senescence heterogeneity.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39134516","citation_count":20,"is_preprint":false},{"pmid":"21282977","id":"PMC_21282977","title":"HMGA1-dependent and independent 7SK RNA gene regulatory activity.","date":"2011","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/21282977","citation_count":20,"is_preprint":false},{"pmid":"35238991","id":"PMC_35238991","title":"MicroRNA-24-3p promotes skeletal muscle differentiation and regeneration by regulating HMGA1.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35238991","citation_count":20,"is_preprint":false},{"pmid":"29622687","id":"PMC_29622687","title":"The Linker Histone GH1-HMGA1 Is Involved in Telomere Stability and DNA Damage Repair.","date":"2018","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29622687","citation_count":20,"is_preprint":false},{"pmid":"35785026","id":"PMC_35785026","title":"HMGA1 Promotes Macrophage Recruitment via Activation of NF-κB-CCL2 Signaling in Hepatocellular Carcinoma.","date":"2022","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/35785026","citation_count":20,"is_preprint":false},{"pmid":"37586214","id":"PMC_37586214","title":"TFAP2A activates HMGA1 to promote glycolysis and lung adenocarcinoma progression.","date":"2023","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/37586214","citation_count":19,"is_preprint":false},{"pmid":"28255749","id":"PMC_28255749","title":"Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas.","date":"2017","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28255749","citation_count":19,"is_preprint":false},{"pmid":"29266325","id":"PMC_29266325","title":"HMGA2, but not HMGA1, is overexpressed in human larynx carcinomas.","date":"2018","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/29266325","citation_count":19,"is_preprint":false},{"pmid":"17723105","id":"PMC_17723105","title":"HMGA1 mediates the activation of the CRYAB promoter by BRG1.","date":"2007","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17723105","citation_count":19,"is_preprint":false},{"pmid":"36635290","id":"PMC_36635290","title":"ST8SIA6-AS1 contributes to hepatocellular carcinoma progression by targeting miR-142-3p/HMGA1 axis.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36635290","citation_count":18,"is_preprint":false},{"pmid":"35822448","id":"PMC_35822448","title":"3'RNA and whole-genome sequencing of archival uterine leiomyomas reveal a tumor subtype with chromosomal rearrangements affecting either HMGA2, HMGA1, or PLAG1.","date":"2022","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35822448","citation_count":18,"is_preprint":false},{"pmid":"33755320","id":"PMC_33755320","title":"GRP75-mediated upregulation of HMGA1 stimulates stage I lung adenocarcinoma progression by activating JNK/c-JUN signaling.","date":"2021","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33755320","citation_count":18,"is_preprint":false},{"pmid":"32989212","id":"PMC_32989212","title":"HMGA1 Promotes Hepatic Metastasis of Colorectal Cancer by Inducing Expression of Glucose Transporter 3 (GLUT3).","date":"2020","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/32989212","citation_count":18,"is_preprint":false},{"pmid":"34716319","id":"PMC_34716319","title":"Overexpression of HMGA1 confers radioresistance by transactivating RAD51 in cholangiocarcinoma.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34716319","citation_count":17,"is_preprint":false},{"pmid":"34170494","id":"PMC_34170494","title":"LncRNA ITGB2-AS1 promotes the progression of clear cell renal cell carcinoma by modulating miR-328-5p/HMGA1 axis.","date":"2021","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/34170494","citation_count":17,"is_preprint":false},{"pmid":"34973275","id":"PMC_34973275","title":"miR-142-3p simultaneously targets HMGA1, HMGA2, HMGB1, and HMGB3 and inhibits tumorigenic properties and in-vivo metastatic potential of human cervical cancer cells.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34973275","citation_count":17,"is_preprint":false},{"pmid":"26296198","id":"PMC_26296198","title":"The Association between HMGA1 rs146052672 Variant and Type 2 Diabetes: A Transethnic Meta-Analysis.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26296198","citation_count":17,"is_preprint":false},{"pmid":"34407055","id":"PMC_34407055","title":"HMGA1 promotes hepatocellular carcinoma proliferation, migration, and regulates cell cycle via miR-195-5p.","date":"2022","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/34407055","citation_count":16,"is_preprint":false},{"pmid":"36352838","id":"PMC_36352838","title":"Mast cells impair melanoma cell homing and metastasis by inhibiting HMGA1 secretion.","date":"2022","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36352838","citation_count":16,"is_preprint":false},{"pmid":"37146833","id":"PMC_37146833","title":"Targeting HMGA1 contributes to immunotherapy in aggressive breast cancer while suppressing EMT.","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37146833","citation_count":16,"is_preprint":false},{"pmid":"29152644","id":"PMC_29152644","title":"HMGA1 participates in MHCC97H cell proliferation and invasion through the ILK/Akt/GSK3β signaling pathway.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29152644","citation_count":16,"is_preprint":false},{"pmid":"25586095","id":"PMC_25586095","title":"Increases urinary HMGA1 in serous epithelial ovarian cancer patients.","date":"2015","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/25586095","citation_count":16,"is_preprint":false},{"pmid":"19633359","id":"PMC_19633359","title":"Interaction between HMGA1 and retinoblastoma protein is required for adipocyte differentiation.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19633359","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51299,"output_tokens":11049,"usd":0.159816,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22091,"output_tokens":7805,"usd":0.15279,"stage2_stop_reason":"end_turn"},"total_usd":0.312606,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"HMGA1 proteins bind preferentially to the narrow minor groove of AT-rich DNA sequences via conserved peptide motifs called 'AT hooks', and can also interact with various protein transcription factors both in vitro and in vivo, forming stereospecific multiprotein complexes ('enhanceosomes') on gene promoter/enhancer regions. The proteins have little secondary structure in solution but assume distinct conformations when bound to DNA or other proteins.\",\n      \"method\": \"In vitro DNA binding assays, protein-protein interaction studies, structural analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — foundational mechanistic biochemical characterization replicated across multiple labs over many years; AT-hook DNA binding and conformational changes upon substrate binding established by multiple orthogonal methods\",\n      \"pmids\": [\"11406267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The human HMG-I(Y) gene produces HMG-I and HMG-Y isoform proteins via alternative splicing of precursor mRNAs, with each of the three different DNA-binding AT-hook domains encoded by sequences on separate exons. Gene transcription is inducible in human lymphoid cells by phorbol esters and calcium ionophores.\",\n      \"method\": \"Gene cloning, sequencing, RT-PCR, chromosomal localization, induction experiments\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct molecular cloning and sequencing establishing gene structure; alternative splicing mechanism confirmed by exon-intron arrangement; inducible expression demonstrated experimentally\",\n      \"pmids\": [\"8414980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"HMGA1(Y) protein directly binds to AT-rich sequences in the 5' regulatory region of the human insulin receptor (INSR) gene, and is required for proper transcription of the INSR gene. Antisense HMGA1(Y) specifically inhibits insulin receptor promoter function and insulin receptor protein expression.\",\n      \"method\": \"Chromatographic purification, EMSA, immunoblot, CAT reporter gene assay, hormone binding studies with antisense RNA cells\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct biochemical purification combined with functional reporter assay and antisense knockdown showing loss of promoter activity and receptor expression; multiple orthogonal methods in single study\",\n      \"pmids\": [\"11156965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"HMGA1b protein overexpression deregulates the cell cycle (cells enter S-phase earlier, G2-M transition delayed) and induces apoptosis through caspase-3 activation in normal rat thyroid cells. The third AT-hook domain and acetylation site K60 are required for induction of apoptosis.\",\n      \"method\": \"Overexpression in PC Cl 3 cells, cell cycle analysis, apoptosis assays, caspase-3 activity measurement, site-directed mutagenesis of AT-hook domain and K60 acetylation site\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis identifying specific functional domains (AT-hook 3 and K60), combined with cell cycle and apoptosis readouts; multiple orthogonal methods in single study\",\n      \"pmids\": [\"11389094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"HMG-I(Y) proteins are in vivo substrates for cell cycle-regulated Cdc2 kinase, which phosphorylates the DNA-binding domain(s), decreasing their substrate binding affinity. This reversible phosphorylation during the cell cycle regulates HMGA1 biological function.\",\n      \"method\": \"In vivo and in vitro kinase assays, DNA binding assays\",\n      \"journal\": \"Progress in cell cycle research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase assays establishing Cdc2 phosphorylation of HMGA1 DNA-binding domain with functional consequence on binding affinity; single review but describing prior experimental work\",\n      \"pmids\": [\"9552376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"HMGA1 protein synthesis is required for thyroid cell transformation by Kirsten murine sarcoma virus. Blockage of HMGA1 via antisense construct prevents the malignant phenotype (anchorage-independent growth, tumor formation) and correlates with absence of AP-1 transcriptional activity induction.\",\n      \"method\": \"Antisense HMGA1 cDNA transfection, soft agar colony formation assay, tumor formation in athymic mice, AP-1 reporter assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined cellular and molecular phenotype readouts (no transformation, no AP-1 activity); in vitro and in vivo confirmation\",\n      \"pmids\": [\"12082527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HMGA1 proteins directly control GATA-1 transcription, negatively regulating it. Loss of HMGA1 in embryonic stem cells causes overexpression of GATA-1, resulting in altered hematopoietic differentiation (reduced monocyte/macrophage population, increased megakaryocyte precursors, increased erythropoiesis). Re-expression of HMGA1 in null ES cells restores wild-type phenotype.\",\n      \"method\": \"Hmga1-null ES cell differentiation assays, gene expression analysis, re-expression rescue experiment\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout and rescue experiments establishing HMGA1 as direct transcriptional regulator of GATA-1 with defined hematopoietic differentiation phenotype; multiple lineage readouts\",\n      \"pmids\": [\"12824305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"HMGA1 directly regulates cardiomyocytic cell growth; haploinsufficiency of Hmga1 in mice causes cardiac hypertrophy. HMGA1 loss also leads to increased RAG1/2 endonuclease expression, abnormal IgH rearrangements, B cell expansion, and hematologic malignancies (B cell lymphoma and myeloid leukemia).\",\n      \"method\": \"Hmga1 heterozygous and homozygous knockout mice, cardiac phenotyping, hematologic analysis, gene expression studies\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic loss-of-function with defined molecular and cellular phenotypes; heterozygous and homozygous mice analyzed\",\n      \"pmids\": [\"16510570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"HMGA1 physically binds the small pocket domain of retinoblastoma protein (RB) and competes with HDAC1 for RB binding. HMGA1 overexpression abolishes RB-mediated repression of E2F-activated transcription from the cyclin E promoter and abrogates RB-mediated G0 arrest under serum starvation.\",\n      \"method\": \"Co-immunoprecipitation, reporter gene assay (cyclin E promoter), serum starvation G0 arrest assay, overexpression in T98G cells\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal protein interaction data combined with functional promoter reporter and cell cycle arrest assay; direct competition with HDAC1 for RB pocket domain established\",\n      \"pmids\": [\"17877762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HMGA1 protein is a novel target of the ATM kinase. An SQ motif on HMGA1 is effectively phosphorylated by ATM in vitro and in vivo. HMGA1 colocalizes with activated ATM (ATM S1981p) and HMGA1 ectopic expression decreases cell survival following ionizing radiation.\",\n      \"method\": \"In vitro and in vivo kinase assays, confocal microscopy colocalization, clonogenic survival assay after ionizing radiation\",\n      \"journal\": \"European journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro kinase assay identifying SQ phosphorylation site, confirmed in vivo, plus colocalization and functional consequence (reduced survival after IR); multiple orthogonal methods\",\n      \"pmids\": [\"18783938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"HMGA1 physically interacts with retinoblastoma protein (RB), C/EBPbeta, and HDAC1. The HMGA1/RB interaction is required for adipocyte differentiation: HMGA1 displaces HDAC1 from the RB-E2F1 complex, enabling CDC25A and CDC6 promoter activation. RB, C/EBPbeta, and HMGA1 cooperate to regulate Id1 and leptin gene transcription. Hmga1-/- ES cells fail to undergo adipocyte differentiation.\",\n      \"method\": \"Co-immunoprecipitation, reporter gene assays (leptin, Id1, CDC25A, CDC6 promoters), Hmga1-/- ES cell differentiation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct protein-protein interaction via Co-IP, multiple promoter reporter assays, genetic knockout phenotype, and displacement of HDAC1 from RB-E2F1 complex established; mechanistic detail confirmed by multiple approaches\",\n      \"pmids\": [\"19633359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"HMGA1 reversibly migrates from nuclei to mitochondria during late S/G2 phases of the cell cycle in normal cells, where it binds mitochondrial DNA (mtDNA). In cancer cells, this controlled shuttling is lost and HMGA1 is found in mitochondria throughout the cell cycle. Elevated HMGA1 levels inversely correlate with mtDNA levels and mitochondrial mass, increase reactive oxygen species (ROS), and decrease efficiency of oxidatively damaged mtDNA repair.\",\n      \"method\": \"Inducible transgenic HMGA1 expression system in MCF-7 cells, mitochondrial fractionation, mtDNA quantification, ROS measurement, mtDNA repair assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — controlled inducible expression system with turn-ON/turn-OFF experiments, subcellular fractionation, multiple functional readouts (mtDNA levels, mass, ROS, repair efficiency); robust mechanistic study\",\n      \"pmids\": [\"19687300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"HMGA1 is a positive regulator of IGF-IR gene transcription. HMGA1 binds directly to the IGF-IR promoter (ChIP assay) and associates with p53 and Sp1. HMGA1 antagonizes p53 inhibitory activity while enhancing Sp1 stimulatory activity on the igf-ir promoter. Silencing HMGA1 decreases IGF-IR expression; forced HMGA1 overexpression increases it.\",\n      \"method\": \"ChIP assay, promoter activity assays, Co-immunoprecipitation (association with p53 and Sp1), siRNA knockdown and overexpression\",\n      \"journal\": \"European journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct ChIP establishing promoter binding, protein-protein interaction via Co-IP, loss- and gain-of-function with functional readouts; multiple orthogonal methods\",\n      \"pmids\": [\"20335021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"7SK small nuclear RNA directly interacts with HMGA1, specifically through the loop 2 (7SK L2) region binding to the first AT-hook motif of HMGA1, competing with DNA binding to the same domain. This interaction regulates over 1500 HMGA1 target genes and affects HMGA1-dependent cell differentiation and proliferation.\",\n      \"method\": \"RNA-protein interaction assays, transcriptome-wide profiling, 7SK substructure inhibition experiments\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct RNA-protein interaction assay identifying specific 7SK loop 2 binding to AT-hook 1 of HMGA1, with competition against DNA binding and genome-wide transcriptional consequences demonstrated\",\n      \"pmids\": [\"21087998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HMGA1 and P-TEFb cooperate in transcriptional activation of select target genes. 7SK RNA complexes containing simultaneously HMGA1 and P-TEFb were identified. 7SK RNA establishes gene-dependent plasticity between HMGA1 chromatin remodeling/transcription initiation and P-TEFb transcription elongation.\",\n      \"method\": \"Transcriptome profiling, dominant-negative Cdk9 inhibition, RNA immunoprecipitation of 7SK complexes containing both HMGA1 and P-TEFb\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-IP detecting ternary complexes, transcriptome profiling of gene co-regulation; single lab but multiple approaches\",\n      \"pmids\": [\"21957495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HMGA1a can cross-link different DNA molecules simultaneously through a novel DNA cross-linking domain identified by point mutagenesis. Overexpression of HMGA1a-eGFP causes chromatin aggregation. Electron microscopy showed HMGA1 creates DNA loops and supercoils in linearized DNA.\",\n      \"method\": \"dSTORM super-resolution microscopy, DNA cross-linking assay, point mutagenesis, electron microscopy\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — novel in vitro cross-linking assay with mutagenesis identifying cross-linking domain, confirmed by super-resolution microscopy and electron microscopy; multiple orthogonal structural/biochemical methods\",\n      \"pmids\": [\"21596776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HMGA1 binds directly to the COX-2 promoter at an AT-rich region in vivo in pancreatic cancer cell lines (ChIP assay) and induces COX-2 expression. Knockdown of HMGA1 represses COX-2. HMGA1 cooperates with activated K-RAS to induce migration, invasion, and anchorage-independent growth.\",\n      \"method\": \"ChIP assay (in vivo promoter binding), siRNA knockdown, overexpression, migration/invasion assays, xenograft tumor formation\",\n      \"journal\": \"Pancreatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vivo promoter occupancy by ChIP, loss-of-function phenotype, in vivo xenograft confirmation; multiple orthogonal methods\",\n      \"pmids\": [\"22898640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HMGA1 specifically binds to the HIV-1 TAR element, with the binding interface overlapping the Tat binding site. HMGA1 and Tat compete for TAR binding. 7SK RNA competes with TAR for HMGA1. HMGA1 negatively influences expression from HIV-1 promoter in a TAR-dependent manner in the presence and absence of Tat.\",\n      \"method\": \"RNA binding assays, competition experiments, HIV-1 promoter reporter assays, HMGA1 knockdown\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct RNA binding assay and competition with Tat established, reporter assays confirm TAR-dependent transcriptional regulation; single lab\",\n      \"pmids\": [\"23392246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HMGA1 recruits the inactive 7SK/P-TEFb snRNP to cellular gene promoters and the HIV-1 promoter. CTIP2 represses P-TEFb activity in a complex containing 7SK RNA and HEXIM1. HMGA1 knockdown causes loss of CTIP2/7SK/P-TEFb snRNP recruitment to these promoters as shown by ChIP.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), siRNA double knockdown, luciferase reporter assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating HMGA1-dependent promoter recruitment of inactive P-TEFb complex, combined with double-knockdown epistasis; direct mechanism for P-TEFb recruitment established\",\n      \"pmids\": [\"24623795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HMGA1 proteins are able to increase the expression of spindle assembly checkpoint (SAC) genes Ttk, Mad2l1, Bub1, and Bub1b by binding to their promoter regions. HMGA1 depletion causes SAC gene downregulation and mitotic defects including unaligned chromosomes in metaphase, reduced prometaphase time, delayed anaphase, and cytokinesis failure.\",\n      \"method\": \"ChIP assay (promoter binding), siRNA knockdown, live-cell microscopy, gene expression analysis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP showing HMGA1 promoter occupancy at SAC genes, live-cell microscopy revealing specific mitotic defects upon depletion; multiple genes and orthogonal methods\",\n      \"pmids\": [\"26009897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"miR-296-5p is repressed in a DNA methylation-dependent manner in glioblastoma stem cells. HMGA1 functions as a downstream effector of miR-296-5p and regulates Sox2 expression by modifying chromatin architecture at the Sox2 promoter, thereby regulating glioblastoma stem cell self-renewal.\",\n      \"method\": \"miR-296-5p overexpression/inhibition, HMGA1 knockdown, chromatin architecture assay at Sox2 promoter, glioma xenograft model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — HMGA1 shown to modulate Sox2 promoter chromatin architecture and act as downstream effector; functional xenograft validation; single lab\",\n      \"pmids\": [\"26898758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"miR-26 silences HMGA1 (and MALT1), thereby dampening NF-κB signaling and TNF-α-induced IL-6 transcription. Knocking down both HMGA1 and MALT1 by RNAi produces NF-κB gene silencing similar to miR-26 overexpression.\",\n      \"method\": \"Transcriptome-wide miR-26 manipulation, RNAi knockdown of HMGA1 and MALT1, NF-κB reporter assay, IL-6 expression analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi epistasis experiment placing HMGA1 in NF-κB signaling downstream of miR-26; transcriptome-wide approach with functional validation; single lab\",\n      \"pmids\": [\"27025651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hmga1 amplifies Wnt/β-catenin signaling to enhance intestinal stem cell self-renewal by upregulating genes encoding Wnt agonist receptors and downstream Wnt effectors. Hmga1 also directly induces Sox9, which is required for Paneth cell differentiation, thereby 'building' an intestinal stem cell niche.\",\n      \"method\": \"Hmga1 transgenic mouse model, gene expression analysis (RNA-seq), ChIP, intestinal organoid assays, in vivo tumor/crypt analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic model combined with ChIP, RNA-seq, and organoid functional assays; multiple orthogonal approaches confirming Wnt amplification and Sox9 induction mechanisms\",\n      \"pmids\": [\"28452345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HMGA1 is a novel transcriptional regulator of the FoxO1 gene. HMGA1 binds directly to the FoxO1 gene promoter (ChIP) and activates FoxO1 gene transcription, increasing FoxO1 mRNA and protein levels in hepatocytes. Forced HMGA1 expression in Hmga1-/- primary hepatocytes rescues FoxO1 expression.\",\n      \"method\": \"Reporter gene assays, ChIP, qRT-PCR, Western blot, primary hepatocyte culture from Hmga1-/- mice, siRNA knockdown\",\n      \"journal\": \"Endocrine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP establishing promoter occupancy, reporter assay, and rescue in knockout hepatocytes; multiple orthogonal methods in single study\",\n      \"pmids\": [\"29052178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"G9a/EHMT2 histone methyltransferase modulates hepatic insulin signaling through regulation of HMGA1 expression. G9a knockdown reduces HMGA1 levels and impairs insulin receptor/AKT signaling; overexpression of HMGA1 normalizes impaired insulin signaling in G9a knockdown cells. In db/db mice, restoring G9a upregulates HMGA1 and improves hepatic insulin signaling.\",\n      \"method\": \"G9a siRNA knockdown, HMGA1 overexpression rescue, insulin signaling assays (p-AKT, insulin receptor), in vivo db/db mouse model\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis placing G9a upstream of HMGA1 in insulin signaling; rescue experiment; confirmed in vivo; single lab\",\n      \"pmids\": [\"29101051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HMGA1 directly regulates the transcription of PLAU (urokinase) and SERPINE1 (PAI-1), key components of the Plasminogen activation system. HMGA1 silencing alters the breast cancer cell secretome, reducing pro-migratory and pro-invasive secreted factors.\",\n      \"method\": \"Inducible HMGA1 silencing, iTRAQ LC-MS/MS secretome profiling, promoter binding assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteome-scale secretome profiling combined with direct promoter regulation assays for PLAU and SERPINE1; single lab\",\n      \"pmids\": [\"28924209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Extracellular HMGA1 (eHMGA1) becomes a ligand for the receptor RAGE (Advanced glycosylation end product-specific receptor), inducing pERK signaling and increasing migration and invasion of triple-negative breast cancer cells. Antibodies blocking HMGA1 in the extracellular space impair migration and invasion.\",\n      \"method\": \"HMGA1-blocking antibodies, RAGE receptor binding assays, pERK signaling assay, migration/invasion assays, xenograft models, fluorescence microscopy\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ligand-receptor interaction established with functional signaling readout (pERK); blocking antibody experiments confirm extracellular function; in vivo xenograft validation\",\n      \"pmids\": [\"30135148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PD-L1 directly interacts with HMGA1 in colorectal cancer cells, and HMGA1 upregulation by PD-L1 activates PI3K/Akt and MEK/ERK pathways to promote cancer stem cell expansion and self-renewal. HMGA1 downregulation rescues PD-L1-induced cancer stem cell phenotypes.\",\n      \"method\": \"Co-immunoprecipitation (PD-L1-HMGA1 interaction), Western blot (pathway analysis), tumorsphere assays, HMGA1 knockdown rescue experiments, xenograft mouse model\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single Co-IP establishing interaction, functional rescue experiment and in vivo confirmation; multiple readouts but interaction characterized by single method\",\n      \"pmids\": [\"30776481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HMGA1 negatively regulates NUMB expression at both transcriptional and post-transcriptional levels in glioblastoma stem cells. At the transcriptional level, HMGA1 binds the NUMB promoter and counteracts C/EBP-β. At the post-transcriptional level, HMGA1 regulates MSI1 and miR-146a expression. HMGA1 knockdown-induced NUMB upregulation leads to downregulation of the NOTCH1 pathway.\",\n      \"method\": \"ChIP (HMGA1 binding to NUMB promoter), C/EBP-β competition assay, miR-146a/MSI1 expression analysis, shRNA knockdown, NOTCH1 pathway analysis\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP establishing direct promoter binding and C/EBP-β competition; multiple levels of regulation shown; single lab\",\n      \"pmids\": [\"31116627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HMGA1 overexpression in cardiomyocytes aggravates LPS-induced inflammation and apoptosis by upregulating cyclooxygenase-2 (COX-2). COX-2 inhibitor alleviates this aggravation. HMGA1 knockdown attenuates inflammation but aggravates apoptosis via downregulation of STAT3; STAT3 agonist reverses the anti-inflammatory effect of HMGA1 knockdown but ameliorates LPS-induced apoptosis.\",\n      \"method\": \"Adeno-associated virus-mediated HMGA1 overexpression in mouse heart, siRNA knockdown in H9c2 cells, COX-2 inhibitor treatment, STAT3 agonist treatment, LPS stimulation, cardiac function assay\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro gain/loss-of-function experiments with pharmacological rescue (COX-2 inhibitor, STAT3 agonist); dual pathway mechanism dissected; single lab\",\n      \"pmids\": [\"32398950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HMGA1 transcriptionally activates RAD51 by binding directly to its promoter through two HMGA1 response elements. HMGA1 overexpression promotes radioresistance in cholangiocarcinoma, while HMGA1 knockdown causes radiosensitivity. Inhibition of RAD51 reverses the effect of HMGA1 on radioresistance.\",\n      \"method\": \"ChIP assay (HMGA1 binding to RAD51 promoter through response elements), RAD51 inhibition rescue experiments, clonogenic survival assay after X-ray irradiation, overexpression/knockdown experiments\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP establishing binding to specific RAD51 promoter response elements, rescue experiment with RAD51 inhibitor, functional radioresistance assay; multiple orthogonal methods\",\n      \"pmids\": [\"34716319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HMGA1 chromatin regulators transactivate GATA2 through sequences near the developmental +9.5 enhancer, increasing chromatin accessibility and recruiting active histone marks (H3K4me3, H3K27Ac). Silencing GATA2 recapitulates most phenotypes of HMGA1 depletion in MPN, and GATA2 re-expression partially rescues leukemogenesis. HMGA1 depletion prevents MPN progression to myelofibrosis in JAK2V617F mice.\",\n      \"method\": \"CRISPR/Cas9, shRNA, and genetic deletion; RNA-sequencing; ChIP-sequencing (HMGA1 occupancy and histone marks); JAK2V617F mouse model; GATA2 rescue experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-seq defining HMGA1 occupancy and active histone marks at GATA2 enhancer; multiple genetic approaches (CRISPR, shRNA, knockout); in vivo mouse model; epistasis via GATA2 rescue; highly rigorous study\",\n      \"pmids\": [\"35286385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HMGA1 directly induces FGF19 expression by recruiting active histone marks (H3K4me3, H3K27Ac) to the FGF19 gene, increasing FGF19 secretion. Disrupting FGF19 (by gene silencing or FGFR4 inhibitor BLU9931) recapitulates HMGA1 deficiency phenotypes: decreased tumor growth and reduced desmoplastic stroma formation in pancreatic cancer models.\",\n      \"method\": \"RNA-sequencing, ChIP (HMGA1 binding and histone marks at FGF19), siRNA gene silencing, FGFR4 inhibitor treatment, KPC mouse model, orthotopic/subcutaneous xenograft models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP showing HMGA1 recruitment of active histone marks at FGF19 locus; multiple in vivo mouse models; pharmacological and genetic epistasis; rigorous multi-method study\",\n      \"pmids\": [\"36919699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HMGA1 acts as a chromatin remodeling factor that promotes binding of activating transcription factor 4 (ATF4) to the SLC7A11 promoter, enhancing SLC7A11 transcription and maintaining intracellular glutathione homeostasis, thereby suppressing ferroptosis and conferring cisplatin resistance in esophageal squamous cell carcinoma.\",\n      \"method\": \"Transcriptome analysis, ChIP assay (HMGA1 and ATF4 at SLC7A11 promoter), ferroptosis assays (MDA measurement, glutathione levels), HMGA1 knockout in syngeneic allograft and genetically engineered mouse models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP establishing HMGA1-facilitated ATF4 binding at SLC7A11 promoter, mechanistic ferroptosis assays, in vivo mouse model validation; multiple orthogonal methods\",\n      \"pmids\": [\"38383528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HMGA1 increases transcriptional activity of SREBP1 on the FASN promoter, leading to increased lipid accumulation and fatty acid synthesis. Conditional knockout of Hmga1 in intestinal epithelium reduces FASN expression and tumor development in a CRC mouse model, while pharmacological FASN inhibition by orlistat reduces tumor growth in HMGA1-overexpressing mice.\",\n      \"method\": \"Conditional knockout (Hmga1△IEC) and knock-in (Hmga1IEC-OE/+) mouse models, AOM/DSS-induced CRC model, dual-luciferase reporter assay (FASN promoter), Western blot, orlistat treatment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional genetic mouse models (KO and KI) combined with promoter reporter assay; pharmacological rescue with FASN inhibitor; in vivo validation; rigorous multi-method approach\",\n      \"pmids\": [\"39548107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NAT10 enhances HMGA1 mRNA stability by catalyzing N4-acetylcytidine (ac4C) modification of HMGA1 mRNA, thereby promoting cell cycle progression and prostate cancer cell proliferation.\",\n      \"method\": \"ac4C acetylation assays, mRNA stability assays, NAT10 knockdown/overexpression, prostate cancer cell proliferation assays\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA modification identified with NAT10 as writer enzyme; mRNA stability consequence established; single lab\",\n      \"pmids\": [\"38922788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HMGA1 drives a specific 3D chromatin organization: HMGA1-dense loci form highly interactive networks, sequestering genes into 3D networks. HMGA1 heterogeneous linear distribution controls high-order chromatin compartmentalization. In the absence of HMGA1, this 3D organization is largely reversed and inflammatory senescence-associated secretory phenotype (SASP) signaling is amplified.\",\n      \"method\": \"Functional genomics (ChIP-seq, Hi-C/3D genome analysis), graph theory analysis, oncogene-induced senescence model, HMGA1 depletion\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — genome-wide ChIP-seq and 3D chromatin organization analysis (Hi-C) combined with functional senescence model and graph theory; mechanistic link between HMGA1 distribution and chromatin compartmentalization established\",\n      \"pmids\": [\"39134516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GRP75 directly binds to HMGA1 protein and inhibits ubiquitination-mediated HMGA1 degradation, thereby stabilizing HMGA1 and causing its upregulation. The GRP75/HMGA1 axis activates JNK/c-JUN signaling in lung adenocarcinoma.\",\n      \"method\": \"Co-immunoprecipitation (GRP75-HMGA1 interaction), ubiquitination assay, GRP75/HMGA1 overexpression and knockdown, JNK/c-JUN pathway analysis, mRNA-sequencing\",\n      \"journal\": \"Thoracic cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct Co-IP and ubiquitination assay establishing GRP75 as a regulator of HMGA1 protein stability; downstream pathway confirmed; single lab\",\n      \"pmids\": [\"33755320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HMGA1 promotes expression of miR-222, which in turn activates PI3K/Akt/MMP9 pathway in uveal melanoma. HMGA1 positively regulates both miR-222 and the PI3K/Akt/MMP9 pathway components in vitro and in vivo.\",\n      \"method\": \"Western blotting, RT-PCR, immunochemistry, xenograft mouse model, miR-222 mimic/inhibitor transfection\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — functional epistasis placing HMGA1 upstream of miR-222 and PI3K/Akt/MMP9, with in vivo confirmation; relationship between HMGA1 and miR-222 identified by bioinformatics and confirmed functionally; single lab\",\n      \"pmids\": [\"31394192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HMGA1 is a polymorphic regulator of VEGFA expression. The HMGA1 rs139876191 variant adversely affects HMGA1 protein expression and function, leading to downregulation of VEGFA expression and protection against proliferative diabetic retinopathy.\",\n      \"method\": \"Case-control association study, HMGA1 variant functional analysis, VEGFA expression assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — functional variant study linking HMGA1 to VEGFA expression regulation; mechanistic link established through protein expression and function assays; single study\",\n      \"pmids\": [\"27991577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"HMGA1 is required for maximal activation of the CRYAB (alphaB-crystallin) promoter by the SWI/SNF chromatin remodeling complex BRG1. HMGA1 binds in vitro and in vivo to an AT-rich sequence within a 30 bp BRG1-response element located at the edge of a positioned nucleosome upstream of the transcription start site.\",\n      \"method\": \"ChIP (HMGA1 binding in vivo), in vitro DNA binding assays, HMGA1 knockdown, promoter mutational analysis, BRG1 overexpression\",\n      \"journal\": \"DNA and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo binding confirmed by ChIP; functional requirement for HMGA1 in BRG1-mediated activation established by knockdown and promoter mutation; single lab\",\n      \"pmids\": [\"17723105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HMGA1 promotes macrophage recruitment in hepatocellular carcinoma by activating NF-κB signaling, which in turn drives CCL2 expression. Pharmacological or genetic inhibition of NF-κB blocks CCL2 upregulation in HMGA1-overexpressing HCC cells. Macrophage depletion with clodronate liposomes abrogates the tumor-promoting effects of HMGA1.\",\n      \"method\": \"NF-κB pharmacological/genetic inhibition, CCL2 quantification (ELISA, qRT-PCR, Western blot), clodronate liposome macrophage depletion, orthotopic HCC xenograft model\",\n      \"journal\": \"Journal of immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic NF-κB inhibition epistasis; macrophage depletion confirms the pathway in vivo; CCL2 as mechanistic output; single lab\",\n      \"pmids\": [\"35785026\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HMGA1 is a non-histone architectural chromatin protein that binds AT-rich DNA via three AT-hook motifs (competing with 7SK RNA for the same domain), bends and cross-links DNA, and functions as a dynamic scaffold for stereospecific enhanceosome assembly on gene promoters; it directly transactivates or represses diverse target genes (INSR, IGF-IR, FoxO1, COX-2, FGF19, GATA2, RAD51, Sox9, SLC7A11, FASN, and others) by recruiting co-activators (Sp1, C/EBPβ, ATF4, SREBP1) or displacing repressors (HDAC1 from RB-E2F1 complexes); its activity is regulated post-translationally by Cdc2-mediated phosphorylation of AT-hook domains (reducing DNA binding during mitosis), ATM-mediated phosphorylation at an SQ motif after DNA damage, ubiquitination (counteracted by GRP75), and ac4C acetylation of its mRNA by NAT10 (increasing stability); HMGA1 also shuttles to mitochondria during late S/G2 to bind mtDNA and regulate mtDNA repair and mitochondrial mass, and secreted extracellular HMGA1 acts as a RAGE ligand to activate pERK signaling and promote cancer cell invasion.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HMGA1 is a non-histone architectural chromatin protein that binds the narrow minor groove of AT-rich DNA through conserved AT-hook motifs, adopts defined conformations only upon substrate binding, and nucleates stereospecific multiprotein 'enhanceosome' complexes on gene regulatory regions [#0, #1]. Beyond simple recognition, it actively reshapes DNA and chromatin: a discrete cross-linking domain lets it bridge separate DNA molecules into loops and supercoils [#15], and at genome scale it organizes high-order 3D chromatin compartments, sequestering HMGA1-dense loci into interactive networks whose loss reverses compartmentalization and amplifies senescence-associated inflammatory signaling [#36]. Acting as a recruiting scaffold, HMGA1 directly occupies the promoters/enhancers of a broad target set and tunes their output by deploying co-activators or histone-mark machinery—activating IGF-IR via Sp1 while antagonizing p53 [#12], inducing FoxO1 [#23], RAD51 [#30], GATA2 through active H3K4me3/H3K27Ac at the +9.5 enhancer [#31], FGF19 [#32], and facilitating ATF4 loading at SLC7A11 and SREBP1 activity at FASN [#33, #34]—and repressing targets such as GATA-1 and NUMB, the latter by counteracting C/EBPβ [#6, #28]. It also cooperates with the SWI/SNF remodeler BRG1 at positioned nucleosomes [#40] and competes with HDAC1 for the RB pocket to relieve RB-mediated repression of E2F targets, driving cell-cycle entry and enabling adipocyte differentiation [#8, #10]. Through these activities HMGA1 governs cell-cycle progression and spindle-assembly-checkpoint gene expression [#3, #19], stem-cell self-renewal via Wnt/β-catenin amplification and Sox9 induction [#22], and tumor-promoting programs spanning invasion, metabolism, and DNA-damage resistance. HMGA1 function is constrained by post-translational and RNA-based regulation: Cdc2 phosphorylates the AT-hooks to lower DNA-binding affinity during the cell cycle [#4], ATM phosphorylates an SQ motif after DNA damage [#9], GRP75 binding blocks ubiquitin-mediated degradation [#37], NAT10-catalyzed ac4C modification stabilizes its mRNA [#35], and 7SK snRNA loop 2 binds AT-hook 1 in direct competition with DNA to reroute thousands of target genes and to deliver the inactive 7SK/P-TEFb snRNP to promoters [#13, #18]. HMGA1 additionally shuttles to mitochondria in late S/G2 to bind mtDNA and modulate mtDNA repair, mitochondrial mass, and ROS [#11], and when secreted acts extracellularly as a RAGE ligand activating pERK to promote cancer cell invasion [#26].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing the gene architecture explained how a single locus generates the HMG-I/HMG-Y isoforms and that each AT-hook DNA-binding domain is encoded on a separate exon, framing HMGA1 as a modular, inducibly expressed DNA-binding protein.\",\n      \"evidence\": \"Molecular cloning, sequencing, RT-PCR, and induction experiments in human lymphoid cells\",\n      \"pmids\": [\"8414980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the in vivo DNA targets of the isoforms\", \"Functional differences between HMG-I and HMG-Y isoforms not resolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identifying Cdc2 phosphorylation of the DNA-binding domains showed that HMGA1 DNA-binding affinity is cell-cycle-regulated, providing the first post-translational control switch for its architectural activity.\",\n      \"evidence\": \"In vivo/in vitro kinase assays and DNA binding assays (review of experimental work)\",\n      \"pmids\": [\"9552376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific phosphorylated residues and quantitative affinity change not detailed in this source\", \"Functional consequence on specific target genes not tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Biochemical and structural characterization established the core mechanism—AT-hook recognition of the AT-rich minor groove, disorder-to-order transition upon binding, and assembly of enhanceosomes—and linked it directly to transcription via the insulin receptor promoter and to cell-cycle/apoptosis control via defined domains.\",\n      \"evidence\": \"In vitro DNA binding and protein interaction studies; INSR promoter purification, EMSA, CAT reporter and antisense; overexpression with AT-hook 3 and K60 mutagenesis in rat thyroid cells\",\n      \"pmids\": [\"11406267\", \"11156965\", \"11389094\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution structure of HMGA1 on DNA not resolved\", \"How enhanceosome co-factor selection is determined not defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Loss-of-function showed HMGA1 is required for oncogenic transformation, establishing it as a functional driver rather than a passive chromatin component, with AP-1 transcriptional activity as a downstream readout.\",\n      \"evidence\": \"Antisense HMGA1 with soft-agar, athymic mouse tumor formation, and AP-1 reporter in Kirsten sarcoma virus-transformed thyroid cells\",\n      \"pmids\": [\"12082527\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct HMGA1 target genes mediating transformation not pinpointed\", \"Mechanistic link to AP-1 not at the DNA-binding level\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Knockout-and-rescue established HMGA1 as a direct negative transcriptional regulator of GATA-1 controlling hematopoietic lineage choice, demonstrating physiological developmental function.\",\n      \"evidence\": \"Hmga1-null ES cell differentiation, expression analysis, and re-expression rescue\",\n      \"pmids\": [\"12824305\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct promoter occupancy at GATA-1 not shown here\", \"Co-factors mediating repression not identified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"In vivo mouse genetics showed Hmga1 dosage controls cardiomyocyte growth and lymphoid genome integrity (RAG1/2, IgH rearrangement), expanding its role to tissue homeostasis and tumor suppression at reduced dosage.\",\n      \"evidence\": \"Hmga1 heterozygous/homozygous knockout mice with cardiac and hematologic phenotyping\",\n      \"pmids\": [\"16510570\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets driving each phenotype not all defined\", \"Mechanism of RAG1/2 derepression unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating HMGA1 binding to the RB pocket in competition with HDAC1, and cooperation with BRG1, established HMGA1 as a regulator of the RB-E2F axis and a partner of chromatin-remodeling machinery.\",\n      \"evidence\": \"Co-IP, cyclin E and CRYAB promoter reporters, G0 arrest assay, ChIP, and BRG1 overexpression\",\n      \"pmids\": [\"17877762\", \"17723105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of RB/HDAC1/HMGA1 competition not quantified\", \"Whether BRG1 cooperation generalizes beyond CRYAB not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identifying ATM phosphorylation of an HMGA1 SQ motif placed HMGA1 within the DNA-damage response and tied its expression to radiation survival.\",\n      \"evidence\": \"In vitro/in vivo kinase assays, confocal colocalization with ATM S1981p, clonogenic survival after ionizing radiation\",\n      \"pmids\": [\"18783938\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of SQ phosphorylation on DNA binding or chromatin not defined\", \"Downstream repair targets not connected here\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Mechanistic dissection in adipogenesis showed HMGA1 displaces HDAC1 from RB-E2F1 to activate CDC25A/CDC6 and cooperates with RB and C/EBPβ on leptin/Id1, while a parallel study revealed cell-cycle-coupled mitochondrial shuttling and mtDNA regulation, broadening HMGA1 beyond nuclear chromatin.\",\n      \"evidence\": \"Co-IP, multiple promoter reporters, Hmga1-/- ES adipocyte differentiation; inducible MCF-7 system with mitochondrial fractionation, mtDNA/ROS/repair assays\",\n      \"pmids\": [\"19633359\", \"19687300\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism targeting HMGA1 to mitochondria not defined\", \"How loss of regulated shuttling in cancer is established not explained\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"ChIP and interaction studies established HMGA1 as a direct IGF-IR promoter activator that antagonizes p53 and enhances Sp1, and the discovery of 7SK snRNA binding AT-hook 1 revealed a competitive RNA switch governing thousands of target genes.\",\n      \"evidence\": \"ChIP, promoter assays, Co-IP with p53/Sp1; RNA-protein interaction mapping to 7SK loop 2 with transcriptome profiling\",\n      \"pmids\": [\"20335021\", \"21087998\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of 7SK loop 2/AT-hook 1 recognition not resolved\", \"Genome-wide rules for DNA-versus-7SK occupancy not defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showing HMGA1 forms 7SK complexes with P-TEFb and possesses an intrinsic DNA cross-linking domain connected its transcriptional output to elongation control and revealed direct DNA-bridging/looping as a structural mechanism.\",\n      \"evidence\": \"RNA-IP of HMGA1/P-TEFb 7SK complexes, dominant-negative Cdk9, transcriptome profiling; cross-linking assay, point mutagenesis, dSTORM and electron microscopy\",\n      \"pmids\": [\"21957495\", \"21596776\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How gene-by-gene plasticity between initiation and elongation is decided not defined\", \"Physiological extent of DNA cross-linking in vivo not quantified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating HMGA1 binding to HIV-1 TAR in competition with Tat, and 7SK competition with TAR, extended the competitive AT-hook/RNA model to viral transcriptional control.\",\n      \"evidence\": \"RNA binding and competition assays, HIV-1 promoter reporters, HMGA1 knockdown\",\n      \"pmids\": [\"23392246\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding awaiting independent confirmation\", \"Physiological relevance during infection not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"ChIP and double-knockdown epistasis established that HMGA1 recruits the inactive CTIP2/7SK/HEXIM1/P-TEFb snRNP to cellular and HIV-1 promoters, defining a direct mechanism for delivering elongation machinery to chromatin.\",\n      \"evidence\": \"ChIP, siRNA double knockdown, luciferase reporter assays\",\n      \"pmids\": [\"24623795\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger for converting recruited P-TEFb from inactive to active not defined\", \"Generality across the genome not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"ChIP plus live-cell imaging showed HMGA1 directly activates spindle-assembly-checkpoint genes (Ttk, Mad2l1, Bub1, Bub1b), linking its transcriptional role to mitotic fidelity.\",\n      \"evidence\": \"ChIP, siRNA knockdown, live-cell microscopy, expression analysis\",\n      \"pmids\": [\"26009897\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-factors at SAC gene promoters not identified\", \"Whether mitotic defects are direct or secondary not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Multiple in vivo and metabolic studies positioned HMGA1 as a hub linking stem-cell niche formation, hepatic insulin signaling, and the secretome—amplifying Wnt and inducing Sox9, activating FoxO1, lying downstream of G9a, and directly driving PLAU/SERPINE1.\",\n      \"evidence\": \"Hmga1 transgenic mice, organoids, ChIP/RNA-seq; ChIP and rescue in Hmga1-/- hepatocytes; G9a knockdown rescue and db/db mice; secretome iTRAQ LC-MS/MS with promoter assays\",\n      \"pmids\": [\"28452345\", \"29052178\", \"29101051\", \"28924209\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single chromatin factor selects such distinct programs in different tissues not defined\", \"Some links (G9a, secretome) from single labs\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identifying secreted HMGA1 as a RAGE ligand activating pERK established an extracellular, receptor-mediated function distinct from its chromatin role.\",\n      \"evidence\": \"Blocking antibodies, RAGE binding and pERK assays, migration/invasion, xenografts, microscopy in triple-negative breast cancer\",\n      \"pmids\": [\"30135148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of HMGA1 secretion not defined\", \"Structural basis of HMGA1-RAGE binding not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"A cluster of cancer studies wired HMGA1 into PD-L1, NUMB/NOTCH, and miR-222/PI3K-Akt-MMP9 circuits, showing both upstream regulation of HMGA1 and its function as a chromatin-level effector counteracting C/EBPβ at NUMB.\",\n      \"evidence\": \"Co-IP (PD-L1), tumorsphere and rescue assays; ChIP at NUMB with C/EBPβ competition and miR-146a/MSI1 analysis; miR-222 mimic/inhibitor with xenografts\",\n      \"pmids\": [\"30776481\", \"31116627\", \"31394192\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PD-L1-HMGA1 interaction rests on a single Co-IP without reciprocal validation\", \"Directness of HMGA1 effects on miR-222 not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"ChIP-defined direct activation of RAD51 and identification of GRP75 as a stabilizer blocking HMGA1 ubiquitination connected HMGA1 to DNA-repair-mediated radioresistance and to control of its own protein turnover.\",\n      \"evidence\": \"ChIP at RAD51 response elements, RAD51-inhibitor rescue, clonogenic survival; Co-IP, ubiquitination assay, JNK/c-JUN pathway analysis\",\n      \"pmids\": [\"34716319\", \"33755320\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase targeting HMGA1 not identified\", \"GRP75 axis from a single Medium-confidence study\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"ChIP-seq and genetic rescue established HMGA1 transactivation of GATA2 at the +9.5 enhancer with deposition of active histone marks as a driver of myeloproliferative neoplasm progression, and a parallel HCC study tied HMGA1 to NF-κB/CCL2-driven macrophage recruitment.\",\n      \"evidence\": \"CRISPR/shRNA/knockout, RNA-seq, ChIP-seq, JAK2V617F mice, GATA2 rescue; NF-κB inhibition, CCL2 quantification, clodronate macrophage depletion, orthotopic HCC model\",\n      \"pmids\": [\"35286385\", \"35785026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How HMGA1 directs histone-mark machinery to specific enhancers not defined\", \"HCC NF-κB axis from a single Medium-confidence study\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"ChIP showed HMGA1 directly induces FGF19 by recruiting active histone marks, with FGF19/FGFR4 mediating tumor growth and desmoplastic stroma, reinforcing HMGA1 as an organizer of active chromatin states at growth-factor loci.\",\n      \"evidence\": \"RNA-seq, ChIP at FGF19, siRNA and FGFR4 inhibitor (BLU9931), KPC and xenograft pancreatic cancer models\",\n      \"pmids\": [\"36919699\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The writer machinery HMGA1 recruits for H3K4me3/H3K27Ac not identified\", \"Whether FGF19 induction is fully cell-autonomous not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A convergent set of studies defined HMGA1 as a chromatin-remodeling facilitator of metabolic and 3D-genome programs—loading ATF4 at SLC7A11 to suppress ferroptosis, boosting SREBP1 at FASN for lipogenesis, shaping high-order chromatin compartments, and being stabilized at the mRNA level by NAT10-mediated ac4C.\",\n      \"evidence\": \"ChIP and ferroptosis assays with KO mouse models (SLC7A11); conditional KO/KI mice and FASN reporter/orlistat (FASN); ChIP-seq/Hi-C senescence model; ac4C and mRNA stability assays with NAT10 manipulation\",\n      \"pmids\": [\"38383528\", \"39548107\", \"39134516\", \"38922788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How HMGA1 linear distribution is read into 3D compartmentalization mechanistically not defined\", \"NAT10/ac4C regulation from a single Medium-confidence study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unifying mechanism for how a single AT-hook architectural protein selects its enormous, context-specific target repertoire—and how its phosphorylation, ubiquitination, ac4C, and 7SK-RNA inputs are integrated to switch between DNA bending, co-factor recruitment, and active-mark deposition—remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of HMGA1 engaging chromatin or co-factors\", \"No predictive rule for tissue-specific target selection\", \"Mechanism of mitochondrial import and secretion uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 2, 12, 15, 16, 19, 23, 30, 31, 40]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [13, 14, 17, 18]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 6, 12, 23, 30, 31, 32, 33, 34]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 2, 11, 31, 36]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [15, 36]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 12, 18, 23, 31, 32]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [15, 31, 32, 36, 40]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3, 4, 8, 10, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [21, 26, 27, 41]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 10, 22]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [11, 33, 34]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [9, 30]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 16, 31, 32]}\n    ],\n    \"complexes\": [\n      \"7SK/P-TEFb snRNP (HMGA1-recruited, with CTIP2/HEXIM1)\",\n      \"HMGA1-enhanceosome\"\n    ],\n    \"partners\": [\n      \"RB1\",\n      \"HDAC1\",\n      \"CEBPB\",\n      \"SP1\",\n      \"TP53\",\n      \"ATF4\",\n      \"RAGE\",\n      \"GRP75\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}